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SUMMARY 
 
Lynch syndrome (LS) is one of the most common hereditary cancer syndromes and may lead 
to cancer development, mainly in colon or in endometrium, for 20 years earlier than in 
general population. LS is an autosomal dominantly inherited disorder, associated with the 
malfunction of a highly conserved postreplicative DNA mismatch repair (MMR) mechanism 
and germline mutations at least in four different MMR genes, MLH1, MSH2, MSH6, and 
PMS2. The MMR genes MSH3 and MLH3 have also been linked to LS but their roles are less 
clear. To be able to offer an appropriate follow-up and genetic counseling to LS families and 
their mutation carriers, they must be diagnosed, which usually starts by studying the cancer 
history in the family and the tumor phenotype of the index patient followed by mutation 
search and pathogenicity assessment of found variations. The amino acid substitutions, 
deletions, and insertions, which change only one amino acid in a protein structure, do not 
necessarily destroy protein and therefore their pathogenicity is difficult to interpret. 
Furthermore, in rare cases, an individual can carry two variations either in the same or 
different MMR genes, which further complicates the pathogenicity assessment. 
DNA MMR corrects mismatches arising mainly during DNA replication. DNA synthesis in 
each cell division is carried out by three major replicative DNA polymerases (Pols) ?, ? and ? 
and their incomplete proofreading activity together with malfunction in MMR leads to the 
accumulation of mismatches in the genome leading to genomic instability and cancer.  
MutS homologue (MSH) MMR proteins form the DNA mismatch recognizing factors MutS? 
(MSH2/MSH6) and MutS? (MSH2/MSH3). One aim in the present study was to analyze the 
substrate efficiencies of MutS? and MutS? by using the functional in vitro MMR assay with 
different substrates and cell lines. The target substrates of MutS? and MutS? have already 
been widely studied. However, the extent of their functional redundancy and clinical 
substance remains unclear. Here, our results show that although MutS? alone seems to be 
responsible for the mismatch and one nucleotide loop repair, MutS? and MutS? have 
functional redundancy in two nucleotide loop repair and MutS? even seems to exceed MutS? 
in that. The finding is clinically relevant since such a strong role in two nucleotide loop repair 
indicates MSH3 deficiency in tumors with low dinucleotide and no mononucleotide repeat 
instability. 
The second aim in the study was to functionally characterize a possible compound effect of 9 
pairs of variants of unknown significance (VUS) found in cancer patients. Four variant pairs 
were shown to be proficient while one VUS, MSH2 c.380A>G was individually assessed 
proficient but in a pair with another VUS deficient. Thus, our results suggest that two 
inherited MMR gene variations in a cancer patient may have a concomitant contribution to 
MMR deficiency. Moreover, the role of this frequently reported MMR gene VUS MSH2 
c.380A>G is especially interesting, since its concomitant defect with another variant could 
finally explain its recurrent occurrence in colorectal cancer patients. Three MSH6 VUS were 
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shown to cause MMR deficiency individually. Furthermore, one separately studied MSH3 
variation was shown to be proficient in MMR. 
The third aim was to study the role of replicative polymerases ? and ? in MMR. Here, we 
demonstrate a proliferating cell nuclear antigen independent interaction between replicative 
DNA polymerases and MSH proteins MSH2 and MSH6 by co-purification as well as by 
conventional and chromatin immunoprecipitation. Chromatin recruitment but not the release 
of MSH2 appears to depend on DNA replication. The novel interaction provides a potential 
mechanism for replication-dependent strand discrimination during MMR. In addition, we 
showed that polymerases of the replication fork have a functional role in human MMR. Our 
data, suggesting that MSH2 and MSH6 physically interact with Pols ? and Pol ?, are in 
accordance with models where MSH proteins are continuously loaded onto chromatin in a 
replication-dependent manner and persist on DNA that has already completed replication. 
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INTRODUCTION  
 
Mismatch repair mechanism (MMR) is responsible for maintaining genomic stability by 
repairing errors produced mainly by DNA polymerase that form during DNA replication 
(Jiricny 2006a). Cells lacking functional MMR are not able to repair DNA mismatches which 
leads to accumulation of mutations in DNA. Mutations can be in important genes regions, 
such as tumor suppressor genes (Umar et al. 2004). Inactivation of these genes is associated 
with tumor development and progression. Mutations of MMR genes, especially MHL1, 
MSH2, and MSH6 are linked to one of the most prevalent dominantly inherited cancer 
syndromes, known as Lynch Syndrome (LS) (Peltomäki et al. 1993; Peltomäki 2005), while 
no predisposing mutations have so far been found in the MSH3. Typical LS mutation carriers 
develop cancer in the colon or endometrium in middle age, on average 20 years earlier than 
than individuals without inherited susceptibility. International Amsterdam criteria (Vasen et 
al. 1991; Vasen et al. 1999) have been developed to facilitate and unify LS diagnosis in all 
over the world enabling indispensable counselling, follow-up and treatments for LS mutation 
carriers.  
 
MMR proteins form functional heterodimer complexes, such as MutS? (MSH2 and MSH6) 
and MutS? (MSH2 and MSH3), which recognize small DNA errors in newly replicated DNA 
(Jiricny 2006a). Most inherited mutations in MMR genes destroy protein structure and their 
pathogenicity is easy to assess. Evaluation of the effect of variations in protein/heterodimer 
structure can be tricky in cases where only one aminoacid is changed in the protein structure, 
however, a small group of cancer patients have inherited more than one variation either in the 
same or different MMR genes. The evaluation of the concomitant effect of such small 
changes is challenging. Several functional assays have been developed to study the molecular 
basis of the MMR mechanism (Ou et  al. 2007), and to facilitate the evaluation of small 
individual and concomitant changes.  
 
The main function of polymerases is to duplicate DNA when cells divide. This process 
requires several DNA polymerases such as ?, ? and ?, which synthesize DNA with high 
fidelity. Fidelity and accuracy of DNA duplication cannot be achieved without functional 
MMR. Thus these two mechanisms are interacting with each others. DNA polymerase ? is 
proposed to take part in the MMR mechanism by replacing incorrect DNA (Longley et al. 
1997). Other polymerases ? and ?, however, are not yet known to take part in MMR. 
 
In this PhD work MutS? and MutS? substrate specificities and efficiencies are investigated 
and the concomitant effects of 9 different MSH2/MSH2, MSH6/MSH6 or MSH2/MSH6 
mutation pairs identified in cancer patients are functionally characterized. In addition, one 
novel MSH3 variation found in a putative LS patient was analysed. Finally it was studied, 
whether and how replicative DNA polymerases ?, ?, and ? are interacting with the MMR 
mechanism. 
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REVIEW OF THE LITERATURE 
 
DNA replication and mismatch repair (MMR) 
DNA replication and replicative polymerases 
 
Precise maintenance of genetic information is essential for every organism. High fidelity 
DNA replication is carried out by the replicative DNA polymerases ?, ? and ? (DNA pols ?, ? 
and ?), however low fidelity in DNA replication leads to the accumulation of mutations, 
which may predispose humans to diseases such as cancer (Jiricny 2006a; McCulloch and 
Kunkel 2008).  
Family B DNA polymerases ?, ? and ? are responsible for DNA synthesis in proliferating 
cells (Figure 1). DNA Pol ? is believed to synthesize the leading strand DNA in a largely 
continuous fashion (Fukui et al. 2004; Pursell et al. 2007), while the Okazaki fragments on 
the lagging strand are synthesized and maturated predominantly by DNA Pol ? (Jin et  al. 
2001; Jin et  al. 2003; Fukui et al. 2004; Garg and Burgers 2005; Nick McElhinny et al. 
2007). DNA Pol ? is the eukaryotic protein which carries DNA primase activity and is 
responsible for primer synthesis both on the leading strand and on each Okazaki fragment of 
the lagging strand (Lehman and Kaguni 1989). It synthesizes the first 10 nucleotides of each 
approximately 250-nucleotide long Okazaki fragments on the lagging strand, constituting 
about 2 % of human DNA (McCulloch and Kunkel 2008). 
Several in vitro studies indicate that proofreading improves replication fidelity even more 
than 100 fold depending on the mismatch, the sequence context and the polymerase. DNA 
Pols ? and ? synthesize the bulk of the human genome with high fidelity and processivity 
(Kunkel and Bebenek 2000; Hubscher et al. 2002; Beard and Wilson 2003; Garg and Burgers 
2005; Hsieh and Yamane 2008; McCulloch and Kunkel 2008). DNA Pol ? possesses poor 
processivity and synthesizes DNA with lower fidelity compared to DNA Pols ? and ? (Garg 
and Burgers 2005). DNA Pol ? lacks proofreading activity and has an error rate of 10-4 to 10-5 
(Hsieh and Yamane 2008; McCulloch and Kunkel 2008). Pol ? is suggested to be responsible 
for pol ? error proofreading (McCulloch and Kunkel 2008), by removing RNA-DNA primers 
synthesized by DNA Pol ? mostly during the maturation process (Pavlov et al. 2006). 
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Figure 1. Replicative polymerases, replication protein A (RPA) and their functions in DNA 
replication. Primary function of Pol ? is the leading strand synthesis (Fukui et al. 2004; Pursell et al. 
2007). Pol ? synthesizes and maturates Okazaki fragments on the lagging strand. Primer synthesis is 
carried out by DNA Pol ? (Lehman and Kaguni 1989). Figure is modified from McCulloch et al. 
2008.  
 
Overview of DNA mismatch repair 
 
The mismatch repair mechanism is best described in bacteria Escherichia coli and in yeast 
Saccharomyces cerevisiae. The first indications of prokaryotic MMR mechanism were 
reported in the early 1980s (Lu et al. 1983; Lu et al. 2005), and a few years later the 
prokaryotic MMR was reconstituted by using purified proteins (Lahue et  al. 1989). A very 
similar repair process was later found in eukaryotic cells (Holmes et al. 1990). Intensive 
research during the last thirty years has demonstrated that the basics of the MMR mechanism 
are very similar in prokaryotes and eukaryotes, indicating similar main protein functions. The 
main difference is that in the eukaryotic MMR mechanism, MutS and MutL homologue 
proteins form functional heterodimer complexes with each others, while in prokaryotes the 
functional complexes are homodimers (Li 2008). 
 
The MMR system increases DNA replication fidelity by repairing postreplicative DNA 
errors, such as single nucleotide mismatches and small insertion-deletion loops (IDLs) 
(Palombo et al. 1996; Jiricny 2006a; Pavlov et al. 2006). Postreplicative errors are suggested 
to arise due to replication slippage (Ellegren 2004). The highly conserved DNA repair 
mechanism protects DNA from errors, which arise in approximately every 106-107 new bases 
(Kolodner and Marsischky 1999). MMR defects may lead to a 1000 fold decrease in 
replication fidelity in mammals (Hsieh and Yamane 2008).  Studies on the MMR partial 
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reaction have demonstrated that the DNA error correction system can be divided into three 
main phases: error detection, strand excision, and synthesis of a new strand.   
 
Human MutS homologues 
 
Five MutS homologues (MSH), MSH2, MSH3, MSH4, MSH5, and MSH6, are recognized in 
human cells. Three MSH proteins form two different heterodimers MutS? (MSH2 and 
MSH6), and MutS? (MSH2 and MSH3), which participate in MMR. The third heterodimer 
consists of MSH4 and MSH5 and is not known to have a function in MMR (Drummond et al. 
1995; Palombo et al. 1995; Acharya et al. 1996; Bocker et al. 1999). The MutS? protein 
complex recognizes base-base mismatches and small IDLs of 1-5 unpaired nucleotides, 
whereas  MutS? mainly recognizes two or more unpaired nucleotides in MMR (Umar et al. 
1994; Drummond et al. 1995; Palombo et  al. 1995; Acharya et al. 1996; Drummond et al. 
1997; Gradia et al. 1997; Genschel et al. 1998; Zhang et al. 2005). MutS? and MutS? possess 
partially overlapping functions. MutS? has a high binding affinity to 2 nt (nucleotide) or 
more IDLs but in contrast, a very low affinity to simple base/base mispairs (Palombo et al. 
1995; Acharya et al. 1996; Palombo et al. 1996), while MutS? has been shown to bind and 
repair both base/base mispairs and IDLs (Drummond et al. 1995; Palombo et al. 1996; 
Genschel et al. 1998).  
 
Both MSH2 and MSH6 proteins can be divided into five functional domains: 1) mismatch 
binding domain (amino acids 1-124 in MSH2 and 362-518 in MSH6), 2) connector domain 
(amino acids 125-297 in MSH2 and 519-717 in MSH6), 3) lever domains (amino acids 300-
456 and 554-619 in MSH2 and 718-934 and 1009-1075 in MSH6) , 4) clamp domains (457-
553 in MSH2 and 935-1008 in  MSH6), and 5) ATPase domain (620-855 in MSH2 and 1076-
1355 in MSH6) (Warren et al. 2007). The MSH proteins are ATPases that possess the Walker 
ATP-binding motif, which contains the highly conserved polypeptide sequence (Jiricny 
2006a). The lesion specificity is believed to lie within the MSH3/MSH6-specific sequences, 
which differ notably between them (Owen et al. 2009). The process through which ADP-
ATP exchange occurs on MSH2 seems to be dependent on the protein it forms a complex 
with: MSH6 requires ATP stabilization, whereas MSH3 requires ATP hydrolysis, both of 
which are dependent on specific lesion binding (Owen et al. 2009).  
 
Importantly, it has been shown that MSH6 (domain 1) is responsible for specific mismatch 
binding in the MutS? complex, while MSH2 makes contact with DNA in an unspecific 
manner (Dufner et al. 2000; Warren et al. 2007). It has also been proposed, however, that the 
mismatch binding site of MSH2 is involved in MutS? mediated MMR and that the DNA-
binding mode of MutS? varies depending on the loop size (Lee et al. 2007; Dowen et al. 
2010; Tseng et al. 2011). The mismatch binding domain in MSH6 includes a conserved Phe-
X-Glu motif which is responsible for specific DNA mispair interaction both in prokaryotic 
MutS complex and in eukaryotic MutS? (Lamers et al. 2000; Obmolova et al. 2000; Warren 
et al. 2007). However, MutS? does not repair base-base mispairs or 1 nucleotide IDLs, even 
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if the Phe-X-Glu motif can be found in MSH3 (Genschel et al. 1998; Tseng et al. 2011). 
Instead MutS? may participate in the processing of the trinucleotide repeat expansions, since 
MutS? has been shown to display identical biochemical and biophysical activity when 
interacting with a (CAG)n hairpin and a mismatch (Tian et al. 2009).  
 
Other proteins and their functions in human MMR 
 
The MMR mechanism requires a set of different proteins to accomplish the entire repair 
process. MutL? is a heterodimer complex composed of MutL homologue (MLH) proteins 
MLH1 and PMS2. The primary function of MutL? is to interact with the MutS? complex and 
increase the detection sensitivity to mispairs and to act as a mediator with the other 
components needed in MMR (Jiricny and Nyström-Lahti 2000). MutS? and MutL? together 
form the so called tertiary complex, which increases heteroduplex specificity (Constantin et 
al. 2005; Zhang et al. 2005). It is suggested that MutL? carries the endonuclease activity and 
therefore is capable of cut starting points to exonucleases (Jiricny 2006b). The endonuclease 
property of MutL? is suggested to be activated by replication factor C (RFC) and 
proliferating cell nuclear antigen (PCNA) (Kadyrov et al. 2006). Another heterodimer 
complex, MutL?, consists of MLH1 and MLH3 proteins. It seems to only take part in MMR 
if MutL? is not available, and even then, it only partially replaces its error-correction function 
(Cannavo et al. 2005; Korhonen et al. 2008).  
 
Proliferating cell nuclear antigen is a sliding clamp, which participates in DNA replication 
and repair, and interacts with MSH2, MSH3, MSH6 and MLH1 (Umar et al. 1996; Gu et al. 
1998; Clark et al. 2000; Bowers et  al. 2001; Kleczkowska et  al. 2001; Essers et al. 2005). 
The main function of PCNA in MMR is the initiation and DNA re-synthesis.  In addition, 
PCNA has two roles affecting MutL? function; first, the clamp is required for endonuclease 
activation and second, PCNA determines the strand direction of MutL? incision (Pluciennik 
et al. 2010). PCNA also assists MutS? and MutS? proteins in mispair localisation during new 
strand synthesis (Lau and Kolodner 2003) and mediates MutS? and MutL? interaction (Iyer 
et al. 2010). PCNA seems to be required for the repair reaction which proceeds to the 3’ nick 
directed but not to the 5’ nick directed (Guo et al. 2004). The primary function of RFC is in 
MutL? activation and to load PCNA on DNA (Kolodner and Marsischky 1999; Tainer et al. 
2010). 
Replication protein A (RPA) has multiple roles in MMR. RPA binds to nicked heteroduplex 
DNA to protect ssDNA from binding to itself during excision and it facilitates the excision 
(Ramilo et  al. 2002; Dzantiev et al. 2004; Zhang et al. 2005). Phosphorylation of RPA 
decreases its DNA binding affinity, however the phosphorylation level of RPA varies during 
different stages of the repair process. RPA is not phosphorylated during excision, which 
increases its binding affinity to DNA. Conversely, while Pol ? creates a new strand, RPA is 
phosphorylated, stimulating re-synthesis (Guo et al. 2006). 
The function of an exonuclease 1 (EXO1) has also been shown to be critical in MMR since 
its inactivation increases misincorporation frequency to 10-3 to 10-6 depending on the 
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sequence context. Although, the reconstituted MMR system requires only EXO1 (Constantin 
et al. 2005; Zhang et al. 2005), a weak mutator phenotype in EXO1 null mice suggests other 
yet unknown exonuclease activities (Amin et al. 2001; Wei et al. 2003) . The main function 
of exonuclease 1 in MMR is DNA and mismatch excision (Jiricny 2006a) and its interaction 
partners are MLH1 and MSH2 (Tishkoff et al. 1997; Schmutte et  al. 1998; Tishkoff et  al. 
1998; Amin et al. 2001; Nielsen et al. 2004; Tran et al. 2004).  
 
In addition to the described proteins above, MMR may need some other protein activities, for 
example high mobility protein group B1 (HMGB1), but their clear role in MMR has not yet 
been shown. HMGB1 interacts with MSH2 and MSH6 in vitro (Yuan et al. 2004) and is 
likely to function as an excision stimulator in MMR. However, HMGB1 may be unnecessary 
when RPA is present (Zhang et al. 2005). Finally, DNA ligase I fills the remaining nicks 
during MMR (Zhang et al. 2005). 
 
In vitro model of MMR  
 
A reconstituted in vitro MMR reaction has been accomplished in two separate studies by 
using purified human proteins (Figure 2, Page 17) (Constantin et al. 2005; Zhang et al. 2005). 
These studies were performed using slightly different combinations of purified proteins, 
which repaired the substrates in a test tube. Bidirectional reactions have also been examined 
by using substrates, which include a single strand nick either in the 5’ or 3’direction from the 
mismatch (Constantin et  al. 2005). The first of these studies reported that in vitro MMR 
requires the activity of a total of 7 components: MutS?, MutL?, RPA, EXO1, PCNA, RFC 
and Pol ? (Constantin et al. 2005). Then it was reported that the repair of a substrate with a 5’ 
nick would not require MutL? activity, while substrate with a 3’ nick does (Constantin et al. 
2005; Zhang et al. 2005; Jiricny 2006a). The second reconstitution study, which mainly 
concentrated on the IDL repair mechanism (Zhang et  al. 2005), demonstrated otherwise 
similar results to the study of Constantin et al. (2005), but suggested that HMGB1 activity 
was also needed.  
 
The results of in vitro mismatch repair studies have been combined to a model that describes 
MMR in detail (Figure 2, Page 17) (Jiricny 2006a). According to this model, the mismatch 
repair process is initiated by the binding of the mismatch recognition factor MutS? or MutS? 
to the mispair, followed by assembly of the repairosome by MutL? (Constantin et al. 2005; 
Zhang et al. 2005).  In Escherichia coli (E. coli), strand discrimination is methyl directed (Lu 
et al. 1983; Lu et al. 2005), whilst in the in vitro model for eukaryotic MMR, the strand 
discrimination is directed by a pre-existing nick, since it is not yet known how strand 
discrimination is determined in eukaryotic cells (Gradia et al. 1997; Gradia et al. 1999). 
Three different models for MMR in eukaryotic cells have been proposed: 1) a sliding clamp 
model (Gradia et al. 1999) or 2) a translocation model (Allen et al. 1997), and 3) a stationary 
model (Junop et al. 2001).  The most recent evidence supports the sliding clamp model 
(Zhang et al. 2005), where the MSH protein heterodimer plays a key role as a protein 
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complex that encircles DNA and allows it to pass freely through the hole in its centre. The 
sliding clamp is activated when it recognizes and binds to a mismatch or IDL, which changes 
its conformation. In the presence of mismatched DNA, MSH heterodimer is wrapped around 
DNA, followed by ADP/ATP exchange, which changes its conformation and leads to its 
release from the mismatch site while leaving the heterodimer closed (Jiricny and Nyström-
Lahti 2000).   
ATP commitment to the tetramer complex causes a conformational change, after which it 
slides upstream in the 5’ direction, reaching first RFC which detaches DNA and then EXO1, 
which binds to the complex. Using purified proteins from human cell extracts it was 
discovered that a nick in the 3’ or 5’ direction from the error directs excision (Genschel and 
Modrich 2003; Dzantiev et al. 2004). According to the simplest model for in vitro 5’ ? 3’ 
strand excision, only MutS?, EXO1, and RPA proteins were needed. The study suggests that 
an activation of EXO1 does not require MutL?, although MutL? increases error dependence 
(Constantin et al. 2005). This is, however, inconsistent with requirements in an in vitro MMR 
assay, where a substrate with a 5’ nick also requires MutL? or MutL? activity (Nyström-Lahti 
et al. 2002; Raevaara et al. 2005; Korhonen et al. 2008). When the in vitro MMR reaction 
includes MutL?, MutS?, EXO1, RPA, PCNA, and RFC proteins, excision is carried out 
regardless of direction of the nick. Furthermore, it was shown more recently that MutL?-
complex may have an endonuclease activity enabling the starting point for exonucleases 
(Jiricny 2006b; Kadyrov et  al. 2006; Kadyrov et al. 2007), while excision is carried out by 
EXO1. Repair in the 3’ direction does not seem to occur in the same way as into the 5’ 
direction, however, here, the RFC protein does not release from DNA during the process, but 
by binding to the 3’ side of the nick, it blocks the EXO1 protein preventing its movement in 
the wrong direction (Kolodner and Marsischky 1999; Jiricny 2006a). In addition, RFC may 
also activate PCNA during MMR (Constantin et al. 2005). 
MutL? also plays a crucial role in termination of the excision, since without it, the excision 
process would continue beyond the mismatch. The function of RPA is to stabilize the single-
stranded gap during the excision and resynthesis. Resynthesis is carried out by pol ? (Longley 
et al. 1997), which is connected to PCNA (Kolodner and Marsischky 1999).   
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Figure 2. Reconstituted in vitro MMR mechanism using purified proteins (Constantin et al. 2005; 
Zhang et al. 2005; Jiricny 2006a). Abbreviations: insertion-deletion loop (IDL), heterodimer complex 
of MSH2 and MSH6 (MutS?), heterodimer complex of MSH2 and MSH3 (MutS?), heterodimer 
complex of MLH1 and PMS2 (MutL?), proliferating cell nuclear antigen (PCNA), replication factor 
C (RFC), exonuclease 1 (EXO1), replication protein A (RPA), polymerase delta (pol ?) and DNA-
ligase I. MutS? or MutS? recognises and binds to an error (IDL or mismatch), MutL? binds to 
MutS???, followed by ATP binding. A conformational change in the tetramer releases it from the 
error, after which it starts to slide along the DNA molecule, reaching a single strand brake (nick). A 
and  B  describe  the  repair  processes  that  have  the  break   in  the  5’  (A)  or  3’  (B)  direction  from the  
error, respectively. A) The tetramer complex slides to upstream from the error and releases RFC 
molecule, which is bound to the 5’ nick. Tetramer releases RFC and binds to EXO1, which actively 
removes the incorrect strand. After excision, PCNA and Pol ? synthesize a new strand and DNA 
ligase I seals the nick. B) The tetramer complex slides to downstream of the mismatch and achieve the 
PCNA protein, which is committed to the 3’ direction, EXO1 binds the complex and its activation 
leads to strand degradation between the nick and the error. RFC prevents degradation to proceed to 
the wrong direction. Finally, pol ?/PCNA fills the gap and DNA ligase I seals the nick. Figure is 
modified from Jiricny 2006a. 
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Link between DNA replication and MMR 
 
The accuracy of DNA replication in the absence of a functional MMR is in the range of 10-7 
to 10-8 base misincorporations per genome (Kunkel and Bebenek 2000; Hsieh and Yamane 
2008; McCulloch and Kunkel 2008). This high fidelity is achieved mainly by a strict 
nucleotide selection at the base incorporation step and by a proofreading exonuclease activity 
of DNA Pols ? and ? (Kunkel and Bebenek 2000; Beard and Wilson 2003; Hsieh and 
Yamane 2008). Although the main function of polymerases is to replicate DNA strands 
during a cell division, another important function is to take part in DNA repair mechanisms. 
Pol delta (Pol ?) is supposed to be a key player in MMR, where the task is to resynthesize the 
excised strand (Longley et al. 1997). 
MMR activity is the highest during the S phase of the cell cycle (Schröering et al. 2007) but 
it is unclear how MMR proteins are recruited to newly replicated DNA. It has been proposed 
that MMR proteins are linked to the replication machinery especially via PCNA, so that 
MutS? is physically attached to it (Kleczkowska et al. 2001). On the other hand, Schröering 
et al. (2007) have shown that MSH proteins are recruited to chromatin after inhibition of 
replication, which led them to suggest that MMR proteins might be recruited to chromatin 
directly by replicative DNA polymerases, instead of other replication fork associated factors. 
However, no rigid evidence was provided for that suggestion. A mechanistic link between the 
replication forks and MSH complex might provide information on unfaithfully replicated 
DNA strands. The nicks are supposed to occur frequently during the replication of Okazaki 
fragments. However, the leading strand is synthesized in a more continuous manner (Fukui et 
al. 2004; Chilkova et al. 2007; Pursell et al. 2007). DNA Pol ? has been shown to catalyze 
the DNA synthesis step in human nuclear extracts (Longley et al. 1997). The role of other 
replicative DNA polymerases has not been addressed, although genetic studies on 
Saccharomyces cerevisiae suggest that exonuclease activities of both Pol ? and Pol ? 
participate in the MMR excision process (Harfe and Jinks-Robertson 2000; Schofield and 
Hsieh 2003). 
 
Lynch syndrome  
 
A large advancement was made in the understanding of the molecular and genetic 
background of Lynch syndrome (LS) (hereditary non-polyposis colorectal cancer syndrome, 
HNPCC; MIM # 120435) in 1993, when the first susceptibility gene MSH2 was mapped to 
the chromosome 2 by a genome-wide search and linkage analysis (Leach et  al. 1993; 
Peltomäki et al. 1993). This was closely followed by the mapping of the second susceptibility 
gene, MLH1, to chromosome 3 (Lindblom et al. 1993; Papadopoulos et al. 1994). Nowadays 
it is known that germline mutations at least in four different MMR genes, MLH1, MSH2, 
MSH6, and PMS2, predispose to LS. MLH1 and MSH2 are the most commonly mutated 
genes in LS and 70-85 % of all reported mutations are found in these genes. The MSH6 
mutations account for about 10 % of LS cases (Peltomäki and Vasen 2004), while only few 
predisposing mutations are reported in PMS2 (www.insight-group.org). Inherited mutations 
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have also been reported in the MutL homologue, MLH3 gene but their predisposition to LS is 
not confirmed (Wu et al. 2001). In contrast, no mutations have so far been found in the MutS 
homologue gene, MSH3, even if the dominant mutator effect (accumulation of the mutations 
in the genome), is connected to MSH3 deficiency (Risinger et al. 1996; de la Chapelle 2004). 
Although, cancer is not generally inherited, it is always a genetic disease. In Finland, 1600 
patients are diagnosed with colon cancer each year, accounting for 5-6 % of all cancer cases 
(Association of the Nordic Cancer Registries, http://www-
dep.iarc.fr/NORDCAN/FI/frame.asp). Of the 1600 cancer patiens, 5–8 % are expected to 
have LS (Peltomäki et  al. 2001; Peltomäki 2005), one of the most common cancer 
syndromes. Lynch syndrome shows high penetrance and an incidence of 1:1000 in the 
general population (Umar et  al. 2004). Each year, the number of new colorectal cancer 
(CRC) cases in the whole world is over 1 million, and about 3 % of them belong to LS 
families; in other words, one for every 35 patients (1/35) who suffer CRC also have LS 
(Hampel et al. 2008; Lynch et al. 2009). 
 
Lynch syndrome is an autosomal dominantly inherited disorder, associated with the 
malfunction of a highly conserved postreplicative DNA MMR mechanism (de la Chapelle 
2004). MMR genes behave like tumor suppressor genes; mutations in both alleles are needed 
to inactivate the gene and start tumorigenesis (Knudson 1971). Thus in LS, only cancer 
susceptibility are inherited and LS mutation carriers need a somatic loss of the wild type 
MMR gene allele to result in defective MMR and progression of tumorigenesis. The main 
features that distinguish LS from sporadic CRC are an earlier average age of cancer onset (45 
years vs. 65 years) and microsatellite instability (MSI) in tumors (Lynch et al. 2009).   
 
Clinical and tumor pathological characteristics of LS 
Family cancer history of a putative LS family 
 
To be able to offer an appropriate follow-up and genetic counselling to LS families and their 
mutation carriers, they must be diagnosed. To facilitate LS diagnostics, the first international 
criteria were already proposed twenty years ago, known as the Amsterdam criteria I (ACI) 
(Vasen et al. 1991), which then were later revised and modified producing the Amsterdam 
criteria II (ACII) (Vasen et al. 1999) and Bethesda guidelines (Table 1) (Umar et al. 2004).  
The first criteria, ACI, which included only colon cancers, were found to be too strict and, 
therefore, later revised to include also some extracolonic cancers frequent in LS patients 
(ACII) (Vasen et al. 1999). The Amsterdam criteria are based on typical LS characteristics 
such as cancers present in successive generations indicating dominant inheritance, low age of 
cancer onset compared to the general population, quite often simultaneous/consecutive 
tumors in a patient, typical tumor spectrum including colorectal and endometrial tumors, and 
an MSI phenotype in a tumor.   
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LS patients carrying MLH1 or MSH2 mutations often display typical clinical and tumor 
pathological features of the syndrome, (Lynch et  al. 2008). Contrary to typical LS 
characteristics, mutations in the MSH6 gene are often associated with a later age of cancer 
onset and low or no MSI in tumors (Wu et al. 1999; Wagner et al. 2001; Berends et al. 2002; 
Hendriks et al. 2004) 
Table 1. International criteria used in LS diagnostics 
Amsterdam criteria I Amsterdam criteria II 
At least 3 relatives with histologically verified 
colorectal cancer: 
1. One is a first-degree relative of the other two; 
2. At least two successive generations affected; 
3. At least one of the relatives with colorectal 
cancer diagnosed at <50 years. of age; 
4. Familial adenomatous polyposis has been 
excluded. 
 
At least 3 relatives with an hereditary nonpolyposis 
colorectal cancer-associated cancer (colorectal cancer, 
endometrial, stomach, ovary, ureter/renal pelvis, brain, 
small bowel, hepatobiliary tract, and skin [sebaceous 
tumors]): 
1. One is a first-degree relative of the other two; 
2. At least two successive generations affected; 
3. At least one of the hereditary nonpolyposis colorectal 
cancer-associated cancers should be diagnosed at <50 
years. of age; 
4. Familial adenomatous polyposis should be excluded in 
any colorectal cancer cases; 
Tumors should be verified whenever possible. 
 
Bethesda guidelines  
1. Colorectal cancer diagnosed in a patient who is less than 50 years of age. 
2. Presence of synchronous or metachronous colorectal, or other HNPCC-associated tumors, a regardless of 
age. 
3. Colorectal cancer with the MSI-High histology diagnosed in a patient who is less than 60 years of age. 
4. Colorectal cancer or HNPCC-associated tumor diagnosed under age 50 years in at least one first-degree 
relative. 
5. Colorectal cancer or HNPCC-associated tumor diagnosed at any age in two first- or second-degree relatives. 
Criteria 4 and 5 have been reworded to clarify the Revised Bethesda Guidelines. 
Modified from Lynch et al. 2008 
 
Microsatellite instability and loss of MMR protein in a tumor 
 
Microsatellites are short repetitive regions in the genome. Approximately 15 % of the human 
genome is repetitive DNA including interspersed repeats, LINE (long interspersed elements) 
and SINE (short interspersed elements) elements, and tandemly repeated elements such as 
satellite, microsatellite, and minisatellite elements. Microsatellites or short tandem repeats 
(STR’S) account for 3 % of the genome. The microsatellite repetitive unit length is 1-6 base 
pairs and whole satellite length is up to 100 kb. It is estimated that human DNA contains 
approximately 500 000 microsatellites locating mostly in introns, but also in promoter areas, 
exons, and untranslated terminal regions.  Dinucleotide is the most common form of a repeat 
unit, followed by mono- and tetranucleotide repeats. Trinucleotide repeats are less frequently 
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seen. The most frequent dinucleotide repeat unit is (CA)n. Repetitive DNA is prone to 
mutations and especially to deletions and insertions, which lead to satellite length variation. 
Length variation in microsatellites is called microsatellite instability (Bennett 2000; 
Subramanian et al. 2003).  
 
MSI is a typical feature of LS tumors (Aaltonen et al. 1993; Ionov et al. 1993; Thibodeau et 
al. 1993). Initially, researchers used a wide range of different markers in MSI studies. In 
1997, in a meeting in Bethesda, researchers reviewed the results collected from 
instability studies to develop the most suitable panel of markers to recognize MSI from 
tumors and consequently created the “Bethesda guidelines” to diagnose LS (Table 1) (Umar 
et al. 2004; Lynch et al. 2008). That marker panel, which consists of two mononucleodide 
markers (BAT25, BAT26) and three dinucleotide markes (D2S123, D5S346, D17S250) 
differentiating CRC tumors with MSI-high (MSH-H), MSI-low (MSI-L) and MSI-stable 
(MSS) phenotypes, has since then been widely used. 
Since MMR deficient cells cannot repair DNA replication slippage errors, MMR deficient 
tumors are strongly associated with microsatellite instability. About 90 % of LS tumors show 
MSI (Aaltonen et al. 1993; Ionov et al. 1993; Thibodeau et al. 1993). However, the degree 
and type of MSI differs from low (at least one marker shows instability) to high, when at least 
40 % of markers are unstable (Umar et al. 2004) and between mono-, di-, tri-, and 
tetranucleotide instability or elevated microsatellite alterations at selected tetranucleotide 
repeats (EMAST)  (Peltomäki and Vasen 2004; Plaschke et al. 2004; Haugen et  al. 2008).  
The MLH1 and MSH2 deficient tumors show typically high MSI and in both mono- and 
dinucleotide repeats, whereas in MSH6 deficient tumors, the level of MSI is generally lower 
(Bhattacharyya et al. 1995; Papadopoulos et al. 1995), and it has been recently shown that 
mononucleotide markers have a high sensitivity to detect MSH6 mutation carriers (de la 
Chapelle and Hampel 2010). MSH6 deficient cells are not able to repair single base 
mismatches, while they retain proficiency to repair two, three, and four base loops 
(Drummond et  al. 1995; Risinger et al. 1996; Umar et al. 1997) thus, causing only 
mononucleotide repeat instability in tumors (Wagner et al. 2001; Plaschke et al. 2004; de la 
Chapelle and Hampel 2010). EMAST and also low dinucleotide repeat instability have 
recently been associated with MSH3 deficiency, both in tumor cell lines and in sporadic 
colorectal tumors, while no MSH3 mutations are found in LS  (Haugen et al. 2008). 
Loss of MMR protein expression is connected to MMR deficiency and, other than MSI, it is 
another typical feature of LS tumors. A mutation in a MMR gene leads to a lack of a 
respective protein in a tumor. Immunohistochemical (IHC) staining of MLH1, MSH2, MSH6 
and PMS2 proteins is a widely used, low cost, and sensitive diagnostic method to study 
MMR deficiences. IHC is based on protein identification by a specific antibody and thus, 
detects both the MMR deficiency and the deficient protein. Sometimes a loss of one MMR 
protein also leads to the degradation of its counterpart. For instance, it has been shown that a 
lack of MSH2 protein in a tumor leads to degradation of MSH6, while only in rare cases 
MSH6 loss causes degradation of MSH2 (Bedeir and Krasinskas 2011). Together IHC and 
MSI analyses form a sensitive tool to diagnose LS tumors. In summary, the data of cancers in 
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a family and results of MSI and IHC analyses form a first step in LS diagnostics. When LS is 
suspected, studies continue with mutation search.  
 
MMR gene regulation changes 
 
A mutation in an LS susceptibility gene leads to MMR malfunction, accumulation of 
mutations across the entire genome, and to genome instability. MSI may lead to inactivation 
of tumor suppressor genes and activation of oncogenes, which contain a repetitive region as a 
target site such as the genes TGF?RII (transforming growth factor ? receptor II), Bax, MSH3, 
and MSH6 (Umar et al. 2004). When a positive MSI phenotype and/or a loss of MMR 
protein(s) is found in a tumor, LS needs to be confirmed by mutation search. Unfortunately, 
in 50 % of the suspected LS cases an inherited predisposing mutation cannot be found in 
known MMR genes (Umar et  al. 2004). One reason for that is that not all MSI positive 
tumors are LS tumors. Although, the MSI phenotype is a hallmark of LS tumors, it is also 
present in approximately 10-15 % of sporadic CRCs and in some other extracolonic cancers 
as well. In contrast to LS, in sporadic tumors MSI is typically caused by epigenetic silencing 
of the MLH1 gene via promoter hypermethylation (Veigl et al. 1998). The epigenetic 
silencing of MLH1 complicates the LS diagnosis, since together with an MSI phenotype, it 
also leads to a loss of the MLH1 protein in a tumor. 
 
It has been suggested that large genomic rearrangements in MSH2 and MLH1 are relatively 
common (Nakagawa et  al. 2003). Recently, several groups have reported that germline 
EPCAM (Epithelial Cell Adhesion Molecule) deletions may also cause LS (Kovacs et al. 
2009; Ligtenberg et al. 2009; Niessen et al. 2009) since 3’ EPCAM deletions cause the 
methylation of the MSH2 promoter and hence silencing of the neighbouring MSH2 gene. 
Furthermore, patients showing 3’ EPCAM mutations almost exclusively represent colon 
cancer (Lynch et al. 2011), although cancer risk is dependent on the size and location of the 
deleted EPCAM region (Kempers et al. 2011; Lynch et al. 2011). Such EPCAM deletion 
may explain MSI and loss of the MSH2 protein in tumors, although patients have no 
mutations in MSH2 (Lynch et al. 2011). 
 
Variations of uncertain significance in MMR genes 
 
 MMR gene variations 
 
Approximately 97 % of all reported LS germline mutations are found in three different MMR 
genes, MLH1, MSH2, and MSH6 (de la Chapelle 2004; Woods et al. 2007). Altogether 1515 
germline variations have been reported in the database; 659 MLH1 (44% of the all identified 
MMR gene variations), 595 MSH2 (39%), 216 MSH6 (14%), and 45 PMS2 (3%) (Woods et 
al. 2007; http://www.insight-group.org/). Regardless of the MMR gene in question, 
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truncating MMR gene mutations, which destroy protein structure, are generally considered to 
be disease causing. The amino acid substitutions, deletions, and insertions, which change 
only one amino acid in a protein structure, do not necessarily destroy protein and therefore 
their pathogenicity is difficult to interpret. A variant of uncertain significance (VUS), also 
known as an unclassified variant, is an alteration in a gene sequence whose association with 
the disease risk is unknown (Goldgar et al. 2008). Today’s focus in international 
collaborative research for gastrointestinal hereditary tumors, is to functionally characterize all 
VUS found in suspected LS families and thus distinguish non-pathogenic variants from 
pathogenic ones facilitating gene testing and genetic counseling in these families (Couch et 
al. 2008). 
 
In silico predictions 
 
The most effective and quick studies to predict the functional effects and assess pathogenicity 
of individual variations are done in silico. These computational analyses mainly identify 
conserved areas of a gene through multiple sequence alignment analyses across numerous 
species, and thereafter, deduce possible functional defects caused by the variation. Due to 
their high sensitivity and specificity (Tavtigian et al. 2008), the best in silico prediction 
algorithms, which have been chosen to analyze the possible effects of the individual MMR 
gene variations, are sorting intolerant from tolerant (SIFT) (Ng and Henikoff 2001) 
(http://sift.jcvi.org/), the multivariate analysis of protein polymorphism (MAPP-MMR) 
(Stone and Sidow 2005; Chao et  al. 2008) (http://mendel.standford.edu/SidowLab/), and 
polymorphism phenotyping (PolyPhen-2 (version 2.1.0; HumDiv)) (Adzhubei et al. 2010) 
(http://genetics.bwh.harvard.edu/pph/). The MAPP-MMR algorithm is not, however, 
compatible for MSH6 VUS predictions. Unfortunately, the pathogenicity caused by two or 
more MMR gene variations in one carrier is also impossible so far to predict in silico and 
requires much more complicated and laborious functional studies. 
 
Homozygous and compound heterozygous mutations in MMR genes 
 
The susceptibility to LS is generally associated with one inherited mutated MMR gene allele, 
however, in rare cases, an individual can carry two MMR gene mutations. The studies on 
phenotype-genotype correlations in individuals who have inherited homozygous or biallelic 
compound heterozygous MMR gene mutations has recently been comprehensively 
summarized (Felton et al. 2007; Wimmer and Etzler 2008; Durno et al. 2010). An individual 
who has inherited a monoallelic MMR mutation has an increased susceptibility to cancer, 
while carriers of homozygous or biallelic compound heterozygous mutations, which severely 
damage the protein structure and function, develop hematological and brain malignancies 
during the first or second decade of life (Felton et al. 2007). In addition, in contrary to LS, the 
normal tissue of mutation carriers is also MMR deficient because of the constitutional 
deficiency (Durno et  al. 2010). Furthermore, distribution of predisposing mutations among 
the MMR genes differs. Compared to approximately 90 % of heterozygous mutations in 
typical LS, only 14 % of biallelic MMR gene mutations predisposing to gastrointestinal 
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cancers are located in MLH1 and MSH2 (de la Chapelle 2004; Durno et al. 2010). The type 
and site of a mutation may also effect the age of cancer onset and tumor spectrum. Generally, 
the more severe the mutation is, the more severe is the phenotype (Felton et al. 2007). 
Approximately, two thirds (2/3) of biallelic mutations are of nonsense, frameshift, or large 
deletion types of mutations, and one third (1/3) are missense, splice site, or in-frame deletion 
mutations (Durno et al. 2010). The family history of a biallelic mutation carrier does not 
typically fulfill ACI/II and suggest LS. Surprisingly, almost 60 % of patients with biallelic 
MMR gene mutations have no past medical or family history suggestive of a hereditary 
cancer syndrome.  
 
A small group of cancer patients have inherited two missense variations (pathogenic or VUS) 
either in a same MMR gene allele (monoallelic), in different MMR gene alleles (biallelic), or 
in different MMR genes. So far, altogether 18 different inherited pairs of MMR gene 
missense variations have been reported (Table 2).  
Table 2. Heterozygous MMR gene missense variations found as pairs in cancer patients.  
Gene(s) Variation I Variation II Cancer type/ 
index patient 
Age 
of 
onset 
Reference 
MLH1/ MLH1 p.Ser44Phe p.Ala441Thr BC 35 (Hackman et al. 1997) 
MLH1/ MLH1 p.Lys618Ala c.606-2A>G CRC/Sarcoma 35/65 (Liu et al. 1999) 
MLH1/ MLH1 p.Val722Ile c.1039 -8T>A CRC 30 (Christensen et al. 2009) 
MLH1/ MLH1 p.Lys618Ala p.Arg659Gln CRC 32 (Raevaara et al. 2005) 
MSH2/ MSH2 p.Asn127Ser p.Ala328Pro CRC 65 (Samowitz et al. 2001) 
MSH2/ MSH2 p.Glu205Gln p.Val367Ile PC 59 (Gargiulo et al. 2009) 
MSH2/ MSH2 p.Gly322Asp p.Asp487Glu EC 57 (Hampel et al. 2006) 
MSH2/ MSH6 p.Ile145Met p.Arg1095His CRC 65/74 (Kariola et al. 2003) 
MSH2/ MSH6 p.Ile145Met p.Leu1354Gln CRC 53 (Kariola et al. 2003) 
MSH2/ MSH6 p.Val923Glu p.Ser1188Asn CRC 70 (Ollila et al. 2006) 
MSH6/ MSH6 p.Cys765Trp p.Val878Ala CRC  31 (Plaschke et al. 2006) 
MSH6/ MSH6 p.Leu435Pro p.Val878Ala EC 59 (Hampel et al. 2006) 
MSH2/MLH3 p.Glu198Gly p.Trp1276Arg CRC 29 (Liu et al. 2003) 
MSH6/MLH3 p.Val878Ala p.Glu1451Lys CRC 45 (Wu et al. 2001) 
MLH1/MSH2 p.Glu460Ala p.Met663fs CRC 53 (Christensen et al. 2008) 
MLH1/MSH2 p.Thr117Met p.Gly322Asp CRC 39 (Lee et al. 2005) 
PMS2/ PMS2 p.Ser46Asn p.Ser46Ile CRA 4 (Jackson et al. 2008) 
MSH2/MLH1/
MSH6 
p.Met688Val p.Thr117Met 
p.Ala1339Val 
CRC 46 (Christensen et al. 2008) 
 
Whether and how a variation pair affects a carrier’s clinical phenotype and cancer risk 
depends on the variations’ locations and pathogenicity: if 1) only one of the variations is 
pathogenic, a carrier is a typical LS mutation carrier;  2) the two variations are in the same 
gene but in both parental alleles and both are pathogenic, a carrier resembles a homozygous 
mutation carrier (Felton et al. 2007); 3) neither of the two variations is pathogenic (Kariola et 
al. 2003), a carrier is not predisposed to cancer more than general population; or 4) 
variations, which are non-pathogenic individually, may increase pathogenicity together 
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(Martinez and Kolodner 2010). A family pedigree including cancer data and mutation carriers 
plays a key role when studying whether variations are located in the same or different 
parental alleles. If two inherited variations are located in a same gene allele, or in different 
MMR genes, a carrier still has one wild type (WT) allele of the gene(s), whereas if they are 
located in the same gene but in different alleles, a carrier has no wild type allele of the gene 
in a constitutive genome (Figure 3). This may impose a difference in cancer susceptibility if 
both variations are pathogenic.  
 
 
 
Figure 3. Description of protein products and heterodimer alternatives (here MutS?) when two 
different variations locate in a same gene (MSH2 or MSH6) A) in one allele, B) in different alleles, or 
C) in different genes (MSH2 and MSH6). 
 
Functional analyses of MMR gene variants 
 
When an inherited MMR gene variation has been identified, it is necessary to determine 
whether it is pathogenic or not. This chapter summarizes the functional assays, which have 
been developed and used by different research groups to test the functional significance of 
MMR variations. Functional assays can be divided into two groups according to their aims; to 
those, which study specific function of the variant protein, and to those, which evaluate 
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MMR repair capacity as a complete process (Ou et al. 2007). The latter group can be further 
divided into in vivo and in vitro assays. Functional analyses, which measure the repair 
capacity of a variant protein, are the most applicable to a general assessment of pathogenicity, 
while the other functional tests may give specific information about the causes of repair 
deficiency and pathogenicity.  
Yeast-based functional assays have been developed based on the fact that the MMR system is 
evolutionarily well conserved (Ou et  al. 2007). Functional yeast assays have been used to 
study variations found in CRC patients by creating a corresponding change in the yeast MMR 
gene, because human proteins are not functional in yeast (Shcherbakova and Kunkel 1999; 
Gammie et al. 2007). In this assay, the variant proteins, which are not able to complement the 
absence of a wild type protein, cause a strong mutator phenotype and are interpreted as 
pathogenic. 
Another functional assay performed in yeast (Saccharomyces cerevisiae) is based on the 
observation that the expression of the human MLH1 WT protein in yeast, prevents its 
functional MMR, while the mutated human MMR protein does not interfere with yeast MMR 
(Shimodaira et al. 1998). This phenomenon is described as a dominant mutator effect. If the 
analyzed protein causes the dominant mutator phenotype, the variant is interpreted as 
pathogenic (Shimodaira et al. 1998; Drotschmann et al. 1999).  
Three slightly different in vitro complementation assays have been published (Marra et  al. 
1998; Nyström-Lahti et al. 2002; Drost et  al. 2010). These assays are based on previous 
studies, which have shown that cell extracts are capable to repair mismatches in artificial 
substrates. The first reported in vitro MMR assay used a bacteriophage derived heteroduplex 
that contains a base pair error in the LacZ ?-complementation gene as a substrate (Marra et 
al. 1998). Cytoplasmic protein extract (CE), which lacks the MMR protein in question, is 
supplemented with recombinant MMR protein (WT or variant) produced in insect cells and 
incubated together with the heteroduplex. After the reaction, the heteroduplex is transformed 
into E. coli cells and grown together with the ?-complementation bacterial strain. Functional 
(repaired) LacZ gene increases the number of blue colonies, which indicates a successful 
repair. 
The assay above was modified by complementing MMR deficient human nuclear extracts 
(Nyström-Lahti et al. 2002). This in vitro MMR assay has been especially utilized in 
determining the pathogenicity of the MMR gene variations found in putative LS patients. The 
equivalent missense variations are constructed with a PCR-based site-directed mutagenesis 
method to cDNA and the recombinant MMR proteins produced in a suitable host, such as 
Spodopthera frugiperda 9 insect cells. The ability of a variant protein to repair heteroduplex 
substrates is studied by a complementation assay. If a variant protein restores a repair 
capacity of the deficient nuclear protein extract, which lacks the examined MMR protein, 
repaired heteroduplexes can be cleaved by appropriate restriction enzymes (Lahue et al. 
1989; Holmes et al. 1990; Nyström-Lahti et al. 2002).   
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A cell free assay was recently published, which is very similar to the in vitro MMR assay 
described above (Drost et al. 2010). The main differences between these two assays are in 
protein production and repair detection. Here, variant proteins are produced by the in vitro 
transcription-translation system and successful repair is measured from signals coming from 
fluorescently labelled heteroduplexes. 
To mention some functional assays, which do not assess MMR capacity as a complete 
process but study some specific parts of it, EMSA (electrophoretic mobility shift assay) is a 
method, which can be used to study mismatch binding and  releasing activity of MutS? and 
MutS? protein complexes (Clark et al. 1999; Drotschmann et  al. 1999; Heinen et al. 2002; 
Ollila et al. 2008a; Ollila et al. 2008b). In this method, studied variant proteins are produced 
either in yeast or other suitable host, after which the proteins are purified. The test is based on 
the fact that MMR complexes will bind and release to oligonucleotides that contain a 
mismatch when they are incubated together. The binding can detected by running the samples 
in a native polyacrylamide gel where free oligonuclotides move faster than the ones bound to 
protein complexes. Variations, which affect the normal binding or releasing of complexes, 
are presumed to be pathogenic. 
Several methods to study protein-protein interactions have been developed. For example, 
Glutathione S-transferase (GST) fusion protein interaction method, in which studied proteins 
are produced in vitro, has been successfully used to examine how MMR gene variations 
affect protein-protein interactions. In this assay, the variations, which interfere with 
interaction, are interpreted as pathogenic, while the variations, which do not affect the 
interaction, remain unclear (Guerrette et al. 1998; Guerrette et al. 1999). A co-
immunoprecipitation method, or antibody pull down method, has also been used to study the 
interaction of protein patners in heterodimer complexes (Kariola et al. 2002; Nyström-Lahti 
et al. 2002; Ollila et  al. 2006; Korhonen et al. 2008). Here, MutL? or MutS? protein 
complexes are incubated with an antibody recognizing one of the proteins and after protein 
collection (pulling down), all the proteins in precipitation are analyzed by western blot (WB). 
The interaction is not disturbed if both protein partners are present in equal amounts as in the 
wild type protein complex. The third widely used interaction analysis is a yeast two hybrid 
method which measures physical interaction (in vivo) between two MMR proteins in yeast 
(Kondo et al. 2003). Together with different MMR, mismatch binding, and protein-protein 
interaction assays, there are several other available functional analysis such as subcellular 
localization assays (Raevaara et al. 2005; Gammie et al. 2007), which can be used together 
with the clinical and tumor pathological data  to determine the pathogenicity of MMR gene 
variations.  
 
Pathogenicity assessment of MMR variations 
 
A mutation is a change in DNA sequence, which has an effect on the expression and/or 
function of a gene, whereas a polymorphism is a variation without harmful effect and usually 
frequently present also in the healthy population. It is important for genetic counselling and 
follow-up treatments of carriers in LS or putative LS families that the functional significance 
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and pathogenicity of their variations is understood (Ou et al. 2007; Ou et al. 2008).  
Truncating and splice site mutations are generally shown to cause a complete lack of protein 
or produce a severely damaged protein. The challenge is in the interpretation of missense 
mutations, where only one amino acid is changed in a protein structure. Most of these 
variations are not easy to interpret and often require several functional analyses (Cotton and 
Scriver 1998; Syngal et al. 1999; Nyström-Lahti et al. 2002). Hundreds of VUS have already 
been found and reported in MMR genes and the number is rapidly increasing (www.insight-
group.org). The wide variety of clinical phenotypes in CRC families further complicates 
pathogenicity assessments and LS diagnostics. Non-truncating MMR gene alterations often 
associate with atypical clinical phenotypes with a later age of cancer onset and low or no MSI 
in tumors (Wu et al. 1999; Wagner et al. 2001; Berends et al. 2002; Hendriks et al. 2004); 
since different alterations in a same functional domain and even in a same codon in a MMR 
gene can cause a complete elimination or, in contrast, little to no effect on protein function 
(Ellison et al. 2001; Raevaara et al. 2005). Without pathogenicity assessments based on 
validated biochemical analyses, the increasing number of VUS will reach a bottleneck stage 
in LS diagnostics 
 
Overall, the effects of MMR gene-mutations can be expected to fall into six broad classes: 
interference of DNA binding, loss of ATPase activity, loss of allosteric communication 
between DNA and ATP binding sites, loss of protein-protein interactions with downstream 
effectors, loss of MSH2-MSH6 interaction, and general loss of protein stability (Warren et al. 
2007). A recently established database focusing on missense mutations and small in-frame 
deletions in MMR genes (www.mmruv.info) includes results of functional and/or in silico 
data. At present, the database contains information for 573 variants, 345 in MLH1, 186 in 
MSH2, 20 in MSH6, 11 in PMS2, and 11 in MLH3. Based on the functional data, more than 
half of these variants seem to be pathogenic, underlining the clinical importance of functional 
studies (Ou et al. 2008). 
To facilitate the interpretation of VUS, a decision tree for the in vitro analysis of variants in 
MMR genes in suspected Lynch syndrome cases has been proposed (Couch et al. 2008). This 
model includes three major steps. When family history and/or young age of cancer onset 
predicts LS and results of immunohistochemical, and MSI analyses suggest MMR deficiency 
in a tumor tissue, genetic testing is carried out (Step 1, sequencing of relevant MMR genes). 
When a missense variation (VUS) is identified, the second step (Step 2) dedicated to analyses 
of splice aberrations is (Spurdle et al. 2008), in silico predictions of pathogenicity (Tavtigian 
et al. 2008) and in vitro MMR. If the variant protein retains activity in the in vitro MMR 
assay, more specific functional studies, such as MMR protein stability, protein-protein 
interactions, and protein subcellular localisation studies, need to be carried out in Step 3. 
Deficiency in any of these in vitro assays indicates LS. Recently, a study to verify the three 
step model in pathogenicity assessment performed by using 74 MMR gene VUS (37 MLH1, 
26 MSH2, 11 MSH6) demonstrated how surprisingly appropriate the model for LS 
diagnostics is (Kansikas et al. 2011). 
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AIMS OF THE STUDY 
 
The objective of the study was to functionally characterize MutS homologue mismatch repair 
proteins and their variants (aim 1 and 2). Moreover, the in vitro MMR assay was used to 
functionally evaluate the role of different replicative polymerases, especially pol ? and ? in 
MMR (aim 3). 
 
Specific aims: 
 
1) To determine MutS? and MutS? substrate specificities and MMR efficiencies (I) 
2) The assess the cause of pathogenicity in cases where two inherited MMR gene 
variations are found in cancer patients (II, III)  
3) To study the role of replicative polymerases ? and  ? in MMR (IV) 
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MATERIALS AND METHODS 
 
Descriptions of materials and methods in detail can be found in original articles (I-IV). 
 
Study material 
VUS in studies I, II and III 
 
Studies I, II, and III consist of 9 VUS pairs affecting MMR genes MSH2 (NM_000251.1) 
and/or MSH6 (NM_000179.2). Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence, 
according to www.hgvs.org/mutnomen. The initiation codon is codon 1. Three VUS pairs are 
in the MSH2 gene c.380A>G/c.982G>C; (p.Asn127Ser/p.Ala328Pro) (study III), 
c.613G>C/c.1099G>A; (p.Glu205Gln/p.Val367Ile) (study III), c.965G>A/c.1461C>G; 
(p.Gly322Asp/p.Asp487Glu) (study III), two in the MSH6 gene c.1304T>C/c.2633T>C; 
(p.Leu435Pro/p.Val878Ala) (study III), c.1754T>C/c.2030G>C; (p.Leu585Pro/p.Ser677Thr) 
(study III), and in four pairs there is one VUS in the MSH2 gene and one in the MSH6 gene 
in the same patient c.2726A>T;/c.2633T>C; (p.Lys909Ile/p.Val878Ala) (study III), 
c.435T>G/c.3284G>A; (p.Ile145Met/p.Arg1095His) (study III), c.435T>G/c.4061T>A; 
(p.Ile145Met/p.Leu1354Gln) (study III), p.Val923Glu/p.Ser1188Asn (study II). Of these, the 
VUS pairs p.Lys909Ile/p.Val878Ala and p.Leu585Pro/p.Ser677Thr have not been reported 
before. In addition, the VUS c.2386C>T (p.Arg796Trp) in MSH3 was included in study I. 
The alterations, age of cancer onset, and tumor pathological data of the VUS carriers are 
collected in Table 3. Locations of the variants in the MSH2 and MSH6 functional domains 
are shown in the Figure 4, and the pedigrees of the families are presented in Figure 5. 
 
Figure 4. Locations of the studied VUS in the MutS? functional domains. Functional domains 
adapted from Warren et al. 2007. 
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Table 3. Data of studied VUS and their carriers 
VUS and 
VUS pairs 
Nucleotide 
change  
Protein 
variations  Protein domain
a 
 VUS carrier   
Pedigree/family 
member 
Tumor 
typeb 
Age of 
onset 
MSIc IHCd   
MLH1 MSH2 MSH6 Reference 
MSH2/2 
c.380A>G p.Asn127Ser Connector N/A CRC 65 MSI-H N/A N/A N/A (Samowitz et al. 2001) 
c.982G>C p.Ala328Pro Lever         
c.613G>C p.Glu205Gln Connector Fig. 5A PC 59 N/A N/A N/A N/A (Gargiulo et al. 2009) 
c.1099G>A p.Val367Ile Lever         
c.965G>A p.Gly322Asp Lever N/A EC 57 MSI-L - + - (5%) (Hampel et al. 2006) 
c.1461C>G p.Asp487Glu Clamp         
MSH2/6 
c.435T>G p.Ile145Met Connector Fig. 5B CRC 65/74 MSI-H + + + (Kariola et al. 2003) 
c.3284G>A p.Arg1095His ATPase          
c.435T>G p.Ile145Met Connector Fig. 5C CRC 53 MSI-H + - - (Kariola et al. 2003) 
c.4061T>A p.Leu1354Gln ATPase         
c.2726A>T p.Lys909Ilee ATPase Fig. 5D CRC 79 MSI-H - + + III 
c.2633T>C p.Val878Alae Lever         
c.2768T>A p.Val923Glu ATPase Fig. 5E/a CRC 56 N/A - + ± (Ollila et al. 2006) 
c.3563G>A p.Ser1188Asn ATPase          
c.2768T>A p.Val923Glu ATPase Fig. 5E/b CRC 70 MSS + ± - (Ollila et al. 2006) 
c.3563G>A p.Ser1188Asn ATPase         
c.2768T>A p.Val923Glu ATPase Fig. 5E/c CRA 37 MSI-H N/A N/A N/A (Ollila et al. 2006) 
c.3563G>A p.Ser1188Asn ATPase         
c.2768T>A p.Val923Glu ATPase Fig. 5E/d BCC 52 N/A N/A N/A N/A (Ollila et al. 2006) 
c.3563G>A p.Ser1188Asn ATPase          
MSH6/6 
c.1304T>C p.Leu435Pro Mismatch binding Fig. 5F EC 59 MSI-H + + - (Hampel et al. 2006) 
c.2633T>C p.Val878Ala Lever         
c.1754T>C p.Leu585Proe Connector Fig. 5G CRC 38 MSI-H + + - (eqv.) III 
c.2030G>C p.Ser677Thre Connector         
MSH3 c.2386C>T p.Arg796Trp N/A N/A N/A N/A N/A N/A N/A N/A I 
aAccording to Warren et al. 2007.  bBCC, Basocellular carcinoma; CRC, colorectal cancer; EC, endometrial cancer; PC, pancreatic cancer. cMicrosatellite instability: MSI-H, 
?3 markers indicating MSI; MSI-L, ?2 markers indicating MSI. dImmunohistochemistry: +, present; -, absent; ± reduced or heterogenous expression; N/A, Data not 
available; Eqv., Equivocal. eMutation, MSI and  IHC analysis were performed as described Hampel’s work (Hampel et al. 2005). 
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Figure 5. Pedigrees of the families where the proband carriers two VUS. Arrow and +/+; carrier of two VUS, +/-; carrier has only one VUS. Tumor types and 
ages at cancer onset are marked. Abbreviations of the tumor types: AC; anal cancer, BC; bone cancer, BCC; Basocellular carcinoma, BLAD; bladder cancer, 
BR; brain cancer, BRC; breast cancer, CASU; unknown cancer, CC; cervical cancer, CRA; colorectal adenoma, CRC; colorectal cancer, EC; endometrial 
cancer, HD; Hodking’s lymphoma, LI; liver cancer, LU; lung cancer, OV; ovarian cancer, PC; pancreatic cancer, PR; prostata cancer, SC; stomach cancer.   
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Summary of the methods 
 
All the methods used in the studies are listed in Table 4. 
 
Table 4. Methods used in the studies 
METHOD Additional information Source/reference Used in 
Variant protein production       
PCR: Mutagenesis; 
QuikChange®lightning Site-directed 
mutagenesis  
RefSeg: NM 000251.1 
(MSH2), NM 002439.2 
(MSH3), NM 000179.2 
(MSH6) 
Stratagene I, II, III 
Production of recombinant 
baculoviruses 
Bac-to-bac (Nyström-Lahti et al. 2002) I, II, III 
Production of recombinant proteins Bac-to-bac, Table 5. (Kariola et al. 2002; Ollila et 
al. 2006; Ollila et al. 2008b) 
I, II, III 
Protein analysis       
Western blotting Table 6. (Kariola et al. 2002; Ollila et 
al. 2006; Ollila et al. 2008b) 
I, II, III 
3D analysis  (Berman et al. 2000; Warren 
et al. 2007; Holm and 
Rosenström 2010) 
III 
Functional testing of proteins       
In vitro MMR assay   (Kariola et al. 2002; Nyström-
Lahti et al. 2002; Ollila et al. 
2006)  
I, II, III, IV 
Nuclear protein extraction  (Holmes et al. 1990; Alvino et 
al. 2006) 
I, II, III, IV 
Heteroduplex preparation Figure 6. (Lahue et al. 1989) I, II, III, IV 
Neutralization Table 6.  - IV 
Immunodepletion Table 6.   (Tanaka et al. 1982) IV 
 
 
Cell lines and antibodies 
 
Different cell lines were used for protein production and nuclear protein extraction (Table 5). 
Furthermore, a panel of antibodies was used for protein detection in the western blot analyses 
as well as for immunodepletion and neutralization assays (Table 6).  
 
 
 
 
 
 
 
 
 
34 
 
 
 
Table 5.  Cell lines used in the studies 
Cell lines  Description  Protein deficiencya Sourceb Used in 
GP5d Human colorectal adenocarcinoma cells MSH2, MSH3, MSH6, MLH1 ECACC I 
HCT116  Human colorectal adenocarcinoma cells MLH1, MSH3 ATCC I 
HeLa  Cervix  - ATCC I 
HeLa  Cervix  - M. Frilander, UH II, III, IV 
LoVo Human colorectal adenocarcinoma cells MSH2, MSH3, MSH6 ATCC I, II, III 
Sf9 Insects cells (spodoptera frugiperda)  - Gibco BRL I, II, III 
a(Cannavo et al. 2005), bATCC; American Type Culture Collection, ECACC; European Collection of Cell Culture 
 
Table 6. Antibodies used in the studies 
 
Antigen Antibodies used in western blotting Source Used in 
?-tubulin DM1A, 0,2 mg/ml Sigma I 
MLH1 Clone 168-15, 0,5 mg/ml BD Biosciences/Pharmingen I 
MSH2 MSH2-Ab1, NA-26, 0,2 mg/ml Calbiochem I, II, III 
MSH3 M94120, 250 mg/ml  BD Transduction, Laboratories I 
MSH6 Clone 44, 0,02 mg/ml BD Transduction Laboratories I, II, III 
PMS2 Ab-1, 0,2 mg/ml Calbiochem/Oncogene Research I 
Antigen Antibodies used in neutralisation and immunodepletion Source/Reference Used in 
MSH6 Clone 44, 0,02 mg/ml BD Transduction Laboratories IV 
Pol? SJK-287-38 (Tanaka et al. 1982) IV 
Pol? SJK-132-20 ATCC CRL-1640, protein G, (Tanaka et al. 1982) IV 
Pol? K18 (Pospiech et al. 1999) IV 
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Heteroduplexes used in the in vitro MMR assays 
 
Figure 6 represents substrates which were used in the in vitro MMR assays. Four different 
heteroduplex constructs were prepared: GT mismatch (5’GT), a single (5’IDL1), and two 
nucleotide IDLs (5’IDL2 and 3’IDL2). The protocol for heteroduplex preparation is 
described in Lahues’s work (Lahue et al. 1989). The heteroduplex DNA is a circular 
molecule (3193 bp long) with a single-strand nick upstream or downstream from the site of 
the error. The 5’IDL1 contains a deletion of 1 nt (delA) and 5’- and 3’IDL2 contains a 
deletion of 2 nt (delAT) in the unnicked strand. The GT mismatch was created by replacing 
an adenine with guanine maintaining a thymine on the complementary strand. 
 
 
   
 
Substrate A, B, C D, E E E, C, F 
Used in: I II III IV 
 
 
Figure 6. The substrates used in the in vitro MMR, neutralization, and immunodepletion experiments. 
The bottom strand of the heteroduplex contains a whole BglII -restriction site, whereas the top strand 
contains an error. GT heteroduplex were created by replacing adenine to guanine (A, D). IDLs were 
created by deleting 1 nt (B, E) or 2 nt (C, F) from the top strand. Three different restriction enzymes 
were  used  to  create  a  nick  either  in  the  5’  or  3’  position:   DraIII created a 5’ nick 445 bp from a 
mismatch or IDL (A, B, C),  BanII created a 5’ nick 369 bp from an error (D, E), and AflIII created a 
3’ nick 405 bp from the an IDL (F).  
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RESULTS AND DISCUSSION 
 
In the text, the original figures from the articles (I-IV) are cited by using the number of the 
original article and the Figure. 
 
Mismatch repair analyses of VUS and their pairs (I, II and III) 
 
Clinical and tumor pathological data of the VUS carriers (II, III) 
 
As seen in Table 3, clinical data such as the tumor type, the age of onset, the MSI status, and 
the immunohistochemical (IHC) analysis of the tumors may represent the clinical phenotype 
caused by the coexistence of the two VUS. Excluding the carrier of MSH6 
p.Leu585Pro/p.Ser677Thr, all other compound VUS carriers have a relatively late age of 
cancer onset compared to that typically associated with LS. However, the tumor types such as 
CRC and endometrial cancer affecting most of the carriers as well as the high MSI status seen 
in cases and the protein expression status in their tumors, affecting most of the carriers, 
belong to the typical LS tumor spectrum. However, excluding the patient carrying the pair 
MSH6 p.Leu585Pro/p.Ser677Thr, whose family data showed that the two variations were 
inherited from different parents, and the family pedigrees did not reveal the type of 
inheritance of the two VUS (Figure 5).  Altogether, the families of 4 VUS pair carriers fulfill 
the LS criteria (ACII), families of 3 carriers and do not fulfill, and of 2 families, the data is 
not available. 
 
Concomitant effect of the VUS pairs to MMR deficiency (III) 
 
This study was designed to mimic two different modes of inheritance, where the variations 
are either inherited in a same allele (Figure 3A), in different alleles (Figure 3B) or in different 
genes (Figure 3C). The produced heterodimer protein complexes included either one VUS 
(III, Fig 1a), or a VUS pair (III, Fig 1b), in one of the partners (MSH2 or MSH6) together 
with its wild type (WT) partner (MSH6 or MSH2, respectively) or one VUS in both partners 
(MSH2 and MSH6)  (III, Fig 1c). The amount of variant protein total extract (TE) to be used 
in the in vitro MMR assay was determined by western blot analysis by adjusting the amount 
of its wild type heterodimerization partner in MutS? to be equal to that in the MutS? WT 
complex. Three types of pairs were tested, MSH2/MSH2, MSH2/MSH6 and MSH6/MSH6.  
Protein variant molecules were functionally analysed separately and together with the other 
VUS found in the same patient. The results of in silico predictions, expression stability in Sf9 
cells and MMR capability of the studied variants and variant pairs, are shown in Table 7, in 
page 43. In silico alignment analyses assess each VUS individually, while the functional 
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analysis with the MMR assay allows the assessment of the potential concomitant effect 
caused by two VUS in a carrier.  
By comparing the relative repair efficiencies (III, Figure 2 e), of the MSH2/MSH2 VUS 
pairs p.Asn127Ser/p.Ala328Pro, significantly decreased repair efficiency was demonstrated 
when compared to that of the MutS? WT complex. When individually assayed, p.Asn127Ser 
was able to correct the mismatches as WT (22%, STD ±2% and 19%, STD ±5%, 
respectively) (p=0.25), whereas the repair efficiency of p.Ala328Pro seems to be decreased 
(14%, STD ±3%), although not significantly (p=0.11) (III, Figure 2 a, e). A statistically 
significant decrease in repair efficiency was seen in experiments, when the effect of these 
VUS pairs were tested in the same molecule, MSH2 p.Asn127Ser-p.Ala328Pro (12%, STD 
±4%) and WT (19%, STD ±5%)  (p=0.04) (III, Figure 2 a, e), or in different molecules, 
MSH2 p.Asn127Ser+p.Ala328Pro (14%, STD ±4%) and WT (21%, STD ±1%) (p=0.02) (III, 
Figure 2 d, e), while keeping the total amount of complementing recombinant protein at the 
level of MutS? WT.  
A plausible concomitant contribution to MMR deficiency can be suggested for the MSH2 
pair p.Asn127Ser/p.Ala328Pro. Although when individually assayed with the optimal amount 
of Sf9 total extract, MSH2 p.Asn127Ser indicates proficiency, by halving its amount whilst 
maintaining the total recombinant MutS? amount in the assay at the same level as that of 
MutS? WT. MSH2 p.Asn127Ser cannot complement the deficiency caused by MSH2 
p.Ala328Pro. Instead, their concomitant presence in the assay, either in same or different 
heterodimers, slightly increases the MMR deficiency. According to our previous 
experiments, when the MMR activity of MMR deficient extract is complemented with 
different amounts of WT extract, its optimal amount can be reduced at least by a factor of 10 
without a notable reduction in the repair efficiency (Raevaara et al. 2003).  
Thus, rather than haplo-insufficiency the reason for the concomitant deficiency of MSH2 
p.Asn127Ser/p.Ala328Pro is a functional defect in both. Although, p.Asn127Ser is a rare 
variation, and is generally assessed as a nonpathogenic variation based on several different 
functional studies and healthy phenotype in many mutation carriers, it is among the most 
frequently reported VUS in CRC (Hampel et al. 2006; Ollila et al. 2008a). Thus, together  
with the previous data, the present study implies an extremely subtle MMR defect, which 
may not dominantly predispose to cancer but together with another inherited MMR gene 
variation like with a truncating mutation in MSH2 (c.1264G>T, Glu422Stop) as was reported 
by Tanyi’s work (Tanyi et al. 2008), the MSH2 c.380A>G (p.Asn127Ser) seems to increase 
the cancer risk. In fact, Tanyi and colleagues demonstrated that this could decrease the age of 
cancer onset into the early thirties.  
The original report of the CRC patient carrying the MSH2 variations c.380A>G and 
c.982G>C (Samowitz et al. 2001), unfortunately does not show the data of the other mutation 
carriers and cancers in the family to reveal if the latter variation could already alone 
predispose to cancer. The amino acid change in VUS MSH2 c.982G>C is predicted to be 
deleterious by Polyphen and MAPP-MMR alignment analyses and neutral by SIFT, while 
VUS MSH2 c.380A>G is predicted deleterious by Polyphen and SIFT, but not MAPP-MMR. 
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The mutations were mapped to the structure of the MutS? complex (Warren et al. 2007). 
MSH2 and MSH6 have a similar domain architecture, consisting of 1) a mismatch binding 
domain (1-125/362-519), 2) a connector domain (125-300//519-718), 3) a lever domain (300-
347, 554-620/718-935, 1009-1076), 4) a clamp (457-554/935-1009), and 5) an ATPase 
domain (620-934/1076-1360) (Warren et al. 2007). The substitution p.Ala328Pro maps to a 
long helix in the lever domain (III; Figure 4). The substitution p.Asn127Ser is located in the 
hinge between domains 1 and 2. The distance between the substituted amino acids is fairly 
long (24 Å), and therefore their non-additive effect is due to indirect interactions.  The overall 
structure of the MutS? complex is an oval with allosteric communication between the DNA 
and ATP binding sites (Warren et al. 2007). Crystal structures with multiple substrates and 
normal mode analysis suggest that conserved domain motion is important for allostery 
(Warren et  al. 2007; Mukherjee et al. 2009). More particularly, domains 3 and 5 move 
together as a unit while domain 1 moves a lot during the catalytic cycle (cf. Figure 7 in 
(Warren et al. 2007)).  The introduction of a proline into a helix by the substitution 
p.Ala328Pro is expected to cause a kink in the helix of the lever domain. This could affect the 
allosteric communication between the DNA and ATP binding domains, as the p.Ala328Pro 
mutation alone was shown to mildly impair activity.  The substitution p.Asn127Ser alone in 
the hinge did not impair activity, so we may assume that all rotation states of domain 1 during 
the catalytic cycle remain accessible. The energy landscape, though, may be altered due to 
perturbations of the hydrogen bonds formed by asparagine versus serine side chains. It is not 
impossible that a different transition path may be favoured in the presence of p.Asn127Ser. 
The non-additive impairment seen in the double mutant would also then be explained by 
blockage of the alternative transition path between rotation states for domain 1 in the 
presence of p.Ala328Pro. However, as long as the knowledge about the interactions and 
function of MutS? heterodimer molecules (one or more) with other players in the repair 
complex is under debate, this kind of concomitant contribution cannot be verified by 
biochemical experiments and rather serves as an example of how tricky the interpretation of 
the pathogenicity in vitro can be. 
When the ultimate aim in clinical work is to obtain a classification of the MMR VUS based 
on probability of being pathogenic as was proposed by using five probability classes from 
definitely pathogenic, to not pathogenic, or of no clinical significance (Plon et al. 2008), even 
small differences in repair capability such as is seen between MSH2 p.Ala328Pro alone and 
together with p.Asn127Ser become important, even if the validation assays and their cut offs 
for decision making have not yet been determined. Although the critical level of needed 
repair capability in vivo depends on the circumstances, the concomitant defect of MSH2 
p.Asn127Ser/p.Ala328Pro, which nearly halves the repair capability of MutS? WT, is most 
probably a cause of pathogenicity in the carrier. Especially interesting is the role of MSH2 
c.380A>G, whose effect leading to even slightly increased cancer risk could finally explain 
discrepancies in its repeatedly analyzed proficiency albeit the frequent occurrence in CRC 
patients.  
By comparing the relative repair efficiencies (Table 7; III, Figure 2 e) of the other assayed 
MSH2/MSH2 VUS pairs, p.Gly322Asp/p.Asp487Glu also shows a significantly decreased 
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repair efficiency, whereas MSH2 p.Glu205Gln/p.Val367Ile do not interfere with repair 
capability (Table 7; III, Figure 2 a) when compared to that of the MutS? WT complex. The 
decrease in repair efficiencies was significant when the MSH2 p.Gly322Asp and 
p.Asp487Glu proteins were tested individually (10%, STD ±1% and 10%, STD ± 2%, 
respectively) (p=0.02), and as a pair in the same molecule MSH2 p.Gly322Asp-p.Asp487Glu 
(8%, STD ±3%) (p=0.02) (III, Figure 2 a, e) or in different molecules MSH2 
p.Gly322Asp+p.Asp487Glu (12%, STD ±3%) (p=0.004) (III, Figure 2 d, e). Thus, the pair 
p.Gly322Asp/p.Asp487Glu differs from MSH2 p.Asn127Ser/p.Ala328Pro, which shows 
significantly decreased repair capability only as a VUS pair. Although, different locations of 
the two VUS (either in the same or different molecules) did not significantly affect their 
repair efficiency, the repair efficiencies of MSH2 p.Asn127Ser/p.Ala328Pro and MSH2 
p.Gly322Asp/p.Asp487Glu were lowest when constructed into the same allele suggesting 
stronger impairment on MSH2, MutS?, and its function in a repair complex. 
Variation p.Gly322Asp is among the most frequently reported VUS in CRC (Hampel et al. 
2006; Ollila et al. 2008a), although the majority of the published data discusses p.Gly322Asp 
as a neutral polymorphism (Ollila et al. 2008a; Martinez and Kolodner 2010), it has also been 
hypothesized to be a low penetrance allele, supported by the functional analyses conducted 
with yeast assays (Drotschmann et al. 1999; Ellison et al. 2001). Irrespective of our previous 
study, where the purified p.Gly322Asp variant did not show MMR deficiency (Ollila et al. 
2008a), and the recent studies, where enhancer screens with the yeast homolog msh2 
p.Gly317Asp did not yield enhancer mutations and mouse ECS cells did not show a 
phenotype defect (Martinez and Kolodner 2010; Wielders et  al. 2011), here the protein 
extract with over expressed MSH2 p.Gly322Asp individually and as a pair with p.Asp487Glu 
shows a statistically significant decrease in repair efficiency. It is possible that the 
purification process has at least partly excluded structurally damaged heterodimers 
suggesting that the in vitro MMR assay performed with total extract is more reliable. Overall, 
it seems that results vary a lot dependent on the assay and assay path used for pathogenicity 
assessments. Recent quite comprehensive study of the effect of MSH2 p.Gly322Asp on 
MMR in mouse embryonic stem cells (ESC) demonstrated that expressed from its 
endogenous locus it behaved like wild-type MSH2 (Wielders et al. 2011). The critical 
difference between that and the present study is that the functionality of MSH2 variant is 
assessed in undifferentiated stem cells or in human cell extracts originated from differentiated 
cancer cells, respectively. It is still unexplained why in Lynch syndrome a constitutional 
heterozygous MMR gene mutation predisposes to cancers only in some specific tissues or 
how a human embryo carrying a homozygous MMR gene mutation can succeed through all 
replications and recombinations occurring in several cell divisions and not lead to serious 
consequences until the first or second decade of life. Our results suggest that the in vitro 
MMR assay performed in human based system and thus detecting defective protein function 
in its own environment and repair machinery may reveal problems not detectable in all other 
assay models. 
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Pathogenic MSH6 VUS (II, III) 
 
Although the other studied VUS pairs do not suggest concomitant contribution to MMR 
deficiency, which as such represents important information to the families, three studied 
MSH6 VUS, p.Leu435Pro, p.Leu585Pro, and p.Ser1188Asn, which were previously 
functionally uncharacterized, were found to be unfunctional in the in vitro MMR assay, 
whereas their partners were fully functional (Table 7; II, Figure 2b; III, Figure 2c). 
Furthermore, in silico analysis by Polyphen and SIFT predicts pathogenicity of these MSH6 
variations (Table 7). Consequently, the repair capabilities of the pairs, MSH6 p.Leu435Pro-
p.Val878Asn, MSH6 p.Leu585Pro-p.Ser677Thr and MSH2/MSH6 p.Val923Glu-
p.Ser1188Asn, including both VUS in the same molecule, are also unfunctional (Table 7; II, 
Figure 2b; III, Figure 2b, d, e). Since the western blot analysis of the MMR deficient 
proteins p.Leu435Pro and p.Leu585Pro further revealed their instability (Table 7; III, Figure 
3), the in vitro MMR assay was repeated by using an exaggerated amount of the proteins 
(data not shown). Nevertheless, both variants remained MMR deficient. It was previously 
observed that a leucine to proline change may affect protein stability and/or function. This is 
especially true when such change occurs in a MutS?- connector or mismatch binding site as 
here is the case. Furthermore, it has been reported that substituting leucine to proline in 
MSH2 leads to protein instability (Ollila et al. 2008b).  Our results are also compatible with 
immunohistochemical staining of the tumor showing a lack of MSH6, but presence of MSH2 
and MLH1 (Table 3; Figure 5F/G). Hence the assessment of these two VUS as pathogenic 
mutations is based on several observations: the lack of the MSH6 protein in the tumor tissue, 
instability of the mutated protein in Sf9 expression, and MMR deficiency in the in vitro MMR 
assay, as well as deficiency supported by the in silico analyses. Furthermore, MSH6 
p.Leu435Pro has previously been shown to skip exon 4, already indicating its pathogenicity 
(Hampel et al. 2007). Therefore, there are no additive effects seen when these two mutations 
are paired with other VUS in MSH6 since they sufficiently disrupt MMR function 
independently.   
Other MSH2/MSH6 variants in pairs, including the novel pair p.Lys909Ile/p.Val878Ala, 
showed no significant decrease in the repair capability, nor any evidence of compound 
contribution to MMR deficiency (Table 7; III, Figure 2 b, d, e). Production of MSH2 
p.Val923Glu and MSH6 p.Ser1188Asn and their pair p.Val923Glu/p.Ser1188Asn was 
successful in Sf9 insect cells indicating the stability (Table 7; II, Figure 2a). The functional 
analysis of the two VUS, however, MSH2 (c.2768T>A, p.Val923Glu) and MSH6 
(c.3563G>A, p.Ser1188Asn) revealed that only p.Ser1188Asn was pathogenic in the assay. 
The MSH2 p.Val923Glu variant was previously found to be MMR proficient in the in vitro 
MMR assay, and neutral based on a SIFT (Ollila et al. 2006), but deleterious in Polyphen 
(Table 7). Later, the MSH2 p.Val923Glu variant was, however, suggested to have slightly 
reduced mismatch binding and release capacity compared to the wild type MSH2 protein 
(Ollila et al. 2008b). Here, our results confirm the previous findings and suggest that MSH6 
VUS is the pathogenic mutation in the family. The C-terminal part of the MSH6 polypeptide 
consists of an evolutionarily highly conserved ABC-ATPase domain between amino acids 
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1076-1360. In this sequence, amino acids 1180-1186 form a disordered loop structure, which 
may play a crucial role in ATP binding (Warren et al. 2007). Two cancer associated 
mutations have been reported in the vicinity of that region, the truncating mutation MSH6 
c.3558_3565delTGAAAGTA, p.Gly1186fsX1190, which was detected in a CRC patient at 
the age of 27 (Pinto et al. 2006), and the missense variation, MSH6 c.3577G>A, 
p.Glu1193Lys, which was identified in two endometrial cancer patients with late age of onset 
(59 and 60 years) and poor family history (Kariola et al. 2004). Remarkably, both the 
truncating and the missense variation turned out to be MMR deficient (Kariola et al. 2004; 
Pinto et al. 2006), indicating that the region between amino acids 1186-1193 is extremely 
important in repair function. By supplying evidence, that MSH6 (c.3563G>A, p.Ser1188Asn) 
caused complete loss of protein function in the MMR reaction, our results reinforce the 
impression that this region in MSH6 is particularly important. 
 
Results of mutation analyses as well as tumor analyses including IHC staining of MLH1, 
MSH2, MSH6 and PMS2 proteins, and MSI results are collected in Table 3. Although, the 
IHC analysis shows problems in MSH2 expression in two family members (Table 3; Figure 
5E/a, b) carrying the variations MSH2 (c.2768T>A, p.Val923Glu) and MSH6 (c.3563G>A, 
p.Ser1188Asn), our results demonstrate that the expression problems of both MSH2 and 
MSH6 as well as the high MSI phenotype in one of the mutation carriers (Table 3; Figure 
5E/b) is rather associated with MSH6 than MSH2 deficiency. Since, immunohistochemical 
analysis of MMR protein expression cannot distinguish between EPCAM deletion carriers 
and MSH2 mutation carriers (Kloor et  al. 2011), multiplex ligation dependent probe 
amplification analysis (MLPA) was performed in the carrier 5E/b to exclude a germline 
EPCAM deletion.  
Previously, functionally studied MSH6 VUS have been associated with low cancer 
susceptibility (Kariola et al. 2004). Here, the clinical features such as the late mean age of 
cancer onset (59.5 years), not completely lost but reduced or heterogenous expression of 
MSH6 in the tumor of the mutation carrier (5E/a), and loss of MSH6 expression in the carrier 
(5E/b), support the MSH6 predisposition. Although, the tumors of both mutation carriers 
showed expression deficiencies of MSH6 and MSH2, neither MSH6 p.Ser1188Asn nor 
MSH2 p.Val923Glu, showed expression problems in our in vitro Sf9 expression system 
(Table 7). The explanation for this discrepancy is most probably in the in vitro expression 
system, in which the protein is abundantly expressed under a strong virus promoter. Thus, 
successful MMR protein production in Sf9 insect cells does not necessarily mean stability in 
the tumors and we cannot totally exclude the MSH2 VUS contribution to cancer 
predisposition in these patients. However, its nonpathogenicity was supported by both the in 
vitro MMR and in silico analyses (Polyphen-2 and SIFT), recently found to be a reliable 
assay combination to verify pathogenicity/nonpathogenicity of an MMR VUS (Kansikas et 
al. 2011). Finally, in the fourth generation, there are several family members, who do not 
carry either VUS but still have colorectal adenomas (CRA) at a young age. The fact that  
other MMR gene mutations including large genomic rearrangements in MLH1, MSH2, and 
MSH6, were also excluded, and that all four MMR proteins were normally expressed in their 
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adenomas  (Table 3; Figure 5E/c) suggests that predisposition to CRA in these individuals is 
associated with something other than MMR deficiency. 
Here, it is clearly demonstrated that when LS is suspected, all the MMR susceptibility genes 
should be included in mutation analyses and all identified VUS should be functionally 
assessed. As was seen in this family (Table 3; Figure 5E), when multiple VUS are found in 
the genes MSH2 and MSH6, both genes located on the same chromosome (chromosome 2), 
VUS may show a similar segregation pattern thus, complicate the interpretation.   
 
The functional analysis of an MSH3 variation (I) 
 
The in vitro MMR assay allows functional analysis of all kinds of missense variations in 
different MMR genes, if a suitable cell line, which lacks the analyzed MMR protein, is 
available. Since no LS predisposing mutations have been identified in MSH3 thus  far,  the  
MMR assay was applied here for the first time to test the repair efficiency of an MSH3 
variation c.2386C>T (p.Arg796Trp) found in a putative LS patient (Table 3) (unpublished). 
By comparing the MSH3 variant´s repair efficiency against MSH3-WT´s capability (I, 
Figure  3), results were obtained to suggest that the variant MSH3-R796W is proficient 
(p=0.358) (Table 7). Remarkably, the assay itself functioned well, signifying its utility for 
further MSH3 testing.  
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Table 7. The results of in silico, protein expression and MMR analyses. 
VUS and 
VUS pairs   In silicoa 
Protein 
expression In vitro MMR 
Used 
HDd 
    P S M       
MSH2/2 
p.Asn127Ser - - + Normalb Normalb  
5'IDL1 
p.Ala328Pro - + - Normal Normal  
p.Asn127Ser-p.Ala328Pro N/A N/A N/A Normal Decreasedc  
p.Asn127Ser+p.Ala328Pro N/A N/A N/A N/A Decreased  
p.Glu205Gln + + + Normal Normal 
p.Val367Ile + + + Normal Normal 
p.Glu205Gln-p.Val367Ile N/A N/A N/A Normal Normal 
p.Glu205Gln+p.Val367Ile N/A N/A N/A N/A Normal 
p.Gly322Asp + + + Normal Decreased  
p.Asp487Glu + + + Normal Decreased  
p.Gly322Asp-p.Asp487Glu N/A N/A N/A Normal Decreased  
p.Gly322Asp+p.Asp487Glu N/A N/A N/A N/A Decreased  
MSH2/6 
p.Ile145Met + + - Normal Normal 
5'IDL1 
p.Arg1095His - + N/A Normal Normal 
p.Leu1354Gln - + N/A Normal Normal 
p.Ile145Met-p.Arg1095His N/A N/A N/A Normal Normal 
p.Ile145Met+p.Arg1095His N/A N/A N/A N/A Normal 
p.Ile145Met-p.Leu1354Gln N/A N/A N/A Normal Normal 
p.Ile145Met+p.Leu1354Gln N/A N/A N/A N/A Normal 
p.Lys909Ile - - + Normal Normal 
p.Val878Ala + + N/A Normal Normal 
p.Lys909Ile-p.Val878Ala N/A N/A N/A Normal Normal 
p.Lys909Ile+p.Val878Ala N/A N/A N/A N/A Normal 
p.Val923Glu - + N/A Normal Normal 5'GT 
and 
5'IDL1 
p.Ser1188Asn - - N/A Normal Decreased 
p.Val923Glu-p.Ser1188Asn N/A N/A N/A Normal Decreased 
MSH6/6 
p.Leu435Pro - - N/A Decreasedc Decreased 
5'IDL1 
p.Val878Ala + + N/A Normal Normal 
p.Leu435Pro-p.Val878Ala N/A N/A N/A Decreased Decreased 
p.Leu585Pro - - N/A Decreased Decreased 
p.Ser677Thr + + N/A Normal Normal 
p.Leu585Pro-p.Ser667Thr N/A N/A N/A Decreased Decreased 
MSH3 p.Arg796Trp N/A N/A N/A Normal Normal 5'IDL2 
aPathogenicity predictions by P, Polyphen-2; S, SIFT; M, MAPP-MMR; +, neutral; -, deleterious. bMutated 
protein expressed/functioned as wild type. cMutated protein expressed/functioned abnormally. dUsed 
heteroduplex substrate in the in vitro MMR assay.  
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Substrate specificity and activity of MutS homologue wild type proteins and replicative 
polymerases in MMR (I, IV) 
A strong role of MutS? in dinucleotide loop repair (I, IV) 
 
The in vitro MMR assay is able to demonstrate differences in substrate specificities, as well 
as repair efficiencies of MutS? and MutS?, by using different substrate structures and cell 
lines. In this work, the MMR protein contents of the used cell lines, LoVo, GP5d, and 
HCT116, were first analysed by western blot (I,  Figure  1). This confirmed the absence of 
MSH2, MSH6, and MSH3, in both LoVo and GP5d NEs, thus making them suitable for 
substrate specificity and functionality studies of MutS? and MutS?. The level of PMS2 in 
GP5d NE was also decreased. HCT116 NE only expressed MSH6 and MSH2, presenting an 
opportunity to study the substrate specificity and repair efficiency of MutS? and MutL? with 
it.  
Here, together with different cell lines, three different substrates, 5’GT, 5’IDL1 (delA), and 
5’IDL2 (delAT) were used to study MutS? and MutS? heterodimer complexes. In contrast to 
MutL?, which is known to be essential to all these substrates, the most effective MutS 
complex (MutS? or MutS?) varies depending on the mismatch. The MMR assays with LoVo, 
GP5d, and HCT116, including various combinations of natural or complemented MutL?, 
demonstrated that the role of MutS? is obvious in the repair of 5’GT and 5’IDL1 mismatches, 
whereas an efficient repair of dinucleotide loops requires MutS? (I, Figure 2a, b). 
Remarkably, all the three tested cell lines demonstrate more efficient dinucleotide repair with 
MutS? than with MutS?. In HCT116, the mean repair efficiency was 26% higher (p=0.0014), 
in LoVo 14% higher (p=0.284), and in GP5d 5% higher (p=0.230) with MutS? than with 
MutS?. 
The overlapping roles of these heterodimeric complexes have been previously reported 
(Acharya et al. 1996; Genschel et al. 1998) generally emphasizing the role of MutS? 
predominantly for the recognition of base/base mispairs and small IDLs, and MutS? for the 
recognition of larger (>2bp) IDLs (Acharya et al. 1996; Palombo et  al. 1996; Zhang et al. 
2005). Here, the functional redundancy is supported, but contradictory to the previous 
impression that the repair efficiency of MutS? exceeded that of MutS? in the repair of 
dinucleotide loop structures (Genschel et  al. 1998; Zhang et al. 2005). Although, HCT116 
expressed a sufficient amount of MutS? to repair GT and IDL1 mismatches, the repair 
efficiency of IDL2 was increased three fold when the cells were complemented with MutS? 
(I, Figure 2a, b). The increase in repair efficiencies was also seen in LoVo and GP5d cells 
when complemented with MutS?, but here the differences between MutS? and MutS? were 
not statistically significant as in HCT116. Neutralization of MutS? (MSH6) by MSH6 
antibody reduced the repair of 5’IDL1 by half (IV, Figure 3A), confirming the role of MSH6 
in the repair of small IDLs (Genschel et  al. 1998). In contrast, the repair of a dinucleotide 
loop (3’IDL2) was much less affected by this antibody (IV, Figure 3B) irrespective of the 
site of the nick. Overall, our functional and neutralization assays showed that MutS? not only 
participated but exceeded the IDL2 repair efficiency of MutS?. 
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In cancer diagnostics, the positive MSI phenotype has been a hallmark of LS tumors. 
However, the levels have varied from high to low or no MSI, and between mono-, di-, tri-, 
and tetranucleotide repeat instability, dependent on the MMR gene affected, which might be 
linked to its substrate specificities. HCT116 cells, which are deficient in MLH1 and MSH3, 
have demonstrated mononucleotide repeat stability after complementation with MLH1 
through the addition of chromosome 3, but a low level of dinucleotide and a high level of 
tetranucleotide repeat instability remains, caused by deficiency in MSH3. Although, 
tetranucleotide repeat markers represented a five times higher level of instability than 
dinucleotide markers, supporting the functional overlap of MutS? and MutS? in IDL2 repair. 
Low dinucleotide repeat instability was also caused by defective MutS? (MSH3) (Haugen et 
al. 2008). The microsatellite instability was indeed reversible by complementing HCT116 
cells with both chromosomes 3 and 5, hence expressing both lost proteins MLH1 and MSH3 
(Haugen et  al. 2008). Generally, the MSI marker panel (the Bethesda panel) used in 
diagnostics includes mono- and dinucleotide markers and in MSI positive cases, MLH1, 
MSH2, and MSH6 genes are analyzed for mutations. Our results are clinically relevant, 
emphasizing the importance of MSH3 in dinucleotide loop repair and encouraging MSH3 
mutation analysis, especially when a tumor shows dinucleotide but no mononucleotide repeat 
instability.   
 
? and ? polymerases have a minor role in mismatch repair in vitro (IV) 
 
The aim of the work was to investigate interactions between MSH (MSH2, MSH3, MSH6) 
proteins and replicative polymerases (?, ? and ?) in HeLa cell extracts. Interactions were 
studied from hydroxylapatite-column (HA) fractions, these column separations were part of 
the purification process. Proteins from the polymerase peak fractions were analysed by mass 
spectrometry and western blotting (IV; Figure 1A, B). The catalytic subunit of DNA Pol ? 
and mismatch repair protein MSH2 were identified in certain fractions. Since PCNA was 
removed at an early step of the purification the observed co-purification is not mediated by 
PCNA (IV; Figure S2B). Analysis of the HA fractions revealed that MSH2 was present in 
highly purified Pol ? fractions at nearly stoichiometric amounts, whereas MSH6 and traces of 
MSH3, but no MSH2 was detected in Pol ? peak fractions (IV; Figure 1A). Glycerol 
gradient centrifugation method (GGc) was used to further purify HA polymerase fractions 
which were analysed for the presence of mismatch repair proteins by WB (IV; Figure S3). 
After GGc treatment minor amounts of MSH2 co-sedimented with Pol ?, while MSH6 
migrated more slowly in the gradient, than the polymerase. In the GGc fraction, which 
includes Pol ? only MSH2 co-sedimented, but almost perfectly. Pol ? fraction was pure from 
all contaminating proteins, including MSH2 and MSH6. Physical interaction of MSH2, 
MSH3 and MSH6 proteins with replicative DNA polymerases was further confirmed by 
reciprocal immunoprecipitation (IV; Figure 2A, B).  
The functional characterization of these interactions was performed in the in vitro MMR 
assay  (IV; Figure S3A, B). Neutralization was achieved by incubating HeLa cell extracts 
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with specific antibodies. Neutralization with antibody against MSH6 (IV; Table S1) reduced 
the repair of 5’IDL1 by 50 % (IV; Fig. 3A). This confirms the role of MSH6 in repair of 
small IDLs (Genschel et al. 1998). In contrast, the repair efficiency of a dinucleotide 
insertion (3’IDL2) was decreased only by 10 % (IV; Figure 3B). Antibodies that specifically 
neutralise the activity of human Pols ? and ? have been reported (Tanaka et al. 1982; 
Pospiech et al. 1999; Rytkönen et al. 2006). Neutralization of the polymerase activity of Pol 
? and Pol ? significantly inhibited the repair efficiency of the 5’IDL1 substrate by 13 % 
(p=0.016) and 17 % (p=0.018), respectively (IV; Figure 3A). The 5’IDL2 substrate was also 
inhibited to a similar extent (data not shown). We observed a similar inhibitory effect of Pol ? 
neutralization on the repair of the 3’IDL2 substrate, decreasing the efficiency of repair by 20 
% compared to the complete reaction (p=0.035) (IV; Figure 3B), whereas neutralization of 
Pol ? had no effect on the repair of this substrate. Unfortunately, neutralization of Pol ? was 
not successful (data not shown). 
As neutralization of the polymerase activity of Pol ? resulted only in small although 
reproducible decrease in MMR efficiency of 5’IDL1 substrate, the addition of neutralising 
antibodies would not be enough to completely abolish the polymerase activity. Therefore, the 
requirement of Pol ? in human MMR was further investigated by an immunodepletion assay 
where Pol ? was removed from the HeLa nuclear extract. The depletion was confirmed by 
WB, in which the amounts of other MMR associated proteins remained constant and ?-
Tubulin confirmed equal loading (IV; Figure 4A). In our in vitro MMR analysis HeLa NE 
depleted for Pol ? showed a 10 % decrease (p=0.013) for the comparison of depleted versus 
complete NEs in the repair of the 5’IDL1 substrate (IV; Figure 4B). Moreover, the repair 
defect caused by Pol ? depletion, could be completely reverted by supplementation of the 
extract with highly purified, recombinant Pol ? (IV; Figure 4B and C). By using the 3’IDL2 
substrate, we observed only a insignificant decrease in the repair efficiency (data not shown). 
The effects of Pol ? depletion are in agreement with those of its neutralization. Taken 
together, the results of the MMR activity assay corroborate the requirement of aphidicolin-
sensitive polymerases in the mismatch repair, as was shown previously (Holmes et al. 1990; 
Thomas et al. 1991; Fang and Modrich 1993). While inhibition of Pol ? only affected the 
repair of the substrate with a 5’ nick, Pol ? appears to contribute to the repair of both 5’IDL1 
and 3’IDL2. The moderate effect of antibodies against Pols ? and ? suggests only a minor or 
redundant role for these enzymes. 
After protein interaction and functional studies, the nucleoprotein fraction was used to link 
MMR to the DNA replication apparatus. Highly purified nucleoprotein fractions from HeLa 
cells arrested in early S phase or released to progress to late S phase were prepared. The 
purified the early S phase nucleoprotein fraction contained the licensing factor and helicase 
component MCM3, replicative Pols ?, ? and ? as well as mismatch recognition factors 
MSH2, MSH3 and MSH6 (IV; Figure 5A). The robust increase of MSH2, MSH3 and MSH6 
was seen in fractions in the mid-late S phase and replicative Pols ? and ? in nucleoprotein 
were found to moderately increased towards the mid-late S Phase (IV; Figure 5A, B). In 
addition, the level of MCM3 protein was shown to decrease in mid-late S phase (IV; Figure 
5A, B). Pol ? shows a different, reproducible pattern: chromatin association of the form 
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moving faster in a gel increases during the S-phase while a form moving more slowly 
decreases.  
The association of the MSH protein complex with components of the replication apparatus in 
vivo was characterized by chromatin immunoprecipitation (ChIP), which specifically 
precipitates the chromatin-associated MSH2 and MSH6 (IV; Figure 5C). ChIP was used to 
investigate whether components of the replication machinery were present in the MSH2- and 
MSH6-containing chromatin complexes. The results show that PCNA could be detected in 
the anti-MSH2 and anti-MSH6 precipitates both at early and late time points, although its 
signals in the late S Phase were repeatedly weaker (IV; Figure 5B, C). MCM3 also co-
precipitated with both MSH2 and MSH6 in early and late S Phase. A minor MCM3 signal in 
control IPs was much weaker than the signal in the specific IP, suggesting that MCM3 is 
enriched in MSH2/6-containing, chromatin-associated protein complexes. In addition to 
PCNA and MCM3, we also detected small amounts of the replicative Pols ?, ? and ? in the 
precipitates of nucleoprotein complexes immunoprecipitated by the antibody against MSH6, 
but not by the unspecific control IgG antibody (IV; Figure 5C). We also performed 
reciprocal immunoprecipitations against Pols ?, ? and ? (IV; Figure 5C, lower panels). 
Western blot analyses of the immunoprecipitates for MSH2 and MSH6 confirmed the 
association between MSH2/6 and replicative DNA polymerases. A strong signal of MSH2 
and MSH6 and a milder of MSH3 could be detected in the precipitates of all three replicative 
DNA polymerases.  
Association of MSH2 and MSH6 with replicative DNA polymerases, led to determine if the 
MMR proteins are particularly enriched at origins sites of DNA replication during the S 
phase. Quantitative real time PCR analysis of chromatin precipitates for the enrichment of 
DNA of the well-characterised origins in the LB2 promoter region and the MCM4 upstream 
region suggest that MSH2 associates with the DNA when Orc2 and MCM3 are released from 
the origin, i.e. after origin firing (IV; Figure 6). MSH2, but not Orc2 and MCM3 remains 
associated with the replicated DNA regions at these loci for several hours. The association of 
MSH2 reflects well the observed overall increase of MSH proteins in the nucleoprotein in 
late S phase (IV; Figure 5A). Furthermore, for the two genomic regions investigated, the 
loading of MSH2 appears to follow the origin firing. Once associated with chromatin, MSH2 
persists late into S phase at the sites where DNA replication has already been completed. 
Immunofluorescence technique was used to gain further insight into the relationship between 
MMR and DNA replication, we studied the co-localization of MSH2 with respect to Pol ? 
and PCNA in HeLa cells during S phase. In early S phase HeLa cells both MSH2 and Pol ? 
display punctuate patterns which partly co-localize (IV; Figure 7). However, as S phase 
progresses the degree of co-localization decreases substantially, peaking after 6 hours. 
Immunofluorescence data support our results with chromatin immunoprecipitation (ChIP) 
showing decreasing interaction between MMR and replication machineries during S Phase.  
The data analysis of the extracts and reciprocal precipitation suggests a direct interaction 
between Pol ? and MSH2, and also between Pol ? and MSH6. Furthermore, it can be 
excluded that the interactions described here were mediated by PCNA, since all precipitates 
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presented here were essentially free of PCNA. Altogether, immunoprecipitation studies from 
the nucleoprotein fractions support the results from the conventional precipitations (IV; 
Figure 2A, 2B and 5C) and suggest that MSH complexes are associated with components of 
the DNA replication apparatus including MCM3, PCNA and the replicative Pols ?, ?, and ?, 
assembled on chromatin. All three DNA polymerases precipitated MSH proteins, while 
MSH2 and MSH6 only weakly precipitated Pols. It seems that only a small fraction of the 
chromatin-bound MSH proteins are associated with replicative polymerases and during the 
progression of S phase more MSH proteins are bound to the chromatin without being 
associated directly with active replication forks (IV; Figure 5A and 5C). Therefore, the 
direct interactions between MSH factors and replicative DNA polymerases observed here 
may provide an additional level of regulation of MMR during S phase for the cell.  
Using our in vitro MMR assay, we were able to confirm that mismatch repair is strongly 
inhibited by aphidicolin. The moderate reduction in MMR activity after inhibition of Pols ? 
and ? with neutralising antibodies imply that these DNA polymerases are not mandatory for 
MMR, but may increase the repair efficiency. This is in line with the findings of Longley’s 
work (Longley et al. 1997) where the removal of human Pol ? from cell extracts prevented 
MMR. Pol ? contributed to the repair efficiency of the all three different substrates, while 
neutralisation of Pol ? affected the repair of substrates with a 5’-nick only. One explanation 
for this kind of substrate specificity may be the fact that Pol ? does not possess a 3’-
proofreading exonuclease, whereas Pol ? and ? do. Therefore, it is possible that choice of 
DNA polymerase is not only determined at the re-synthesis step, but already by the 
mechanism of the excision and the location of the nick relative to the mismatch (Dzantiev et 
al. 2004; Guo et al. 2004; Constantin et al. 2005). 
Current understanding of MMR has been largely derived from in vitro assays including 
reconstitution of strand-specific MMR from highly purified factors (Constantin et al. 2005; 
Zhang et al. 2005). However, these in vitro assays do not necessarily take into account the 
cellular context. MMR during the S phase is intertwined with DNA replication, and this 
aspect is not taken into account by commonly used in vitro MMR assays. Cell biological 
studies have shown that MMR proteins can be found at sites of DNA replication during S 
phase (Kleczkowska et al. 2001; Schröering et al. 2007). PCNA is the major candidate for the 
factor that couples MMR to the replication fork, since disruption of the PCNA-MSH3/6 
interaction disrupts association with sites of DNA replication (Clark et  al. 2000; 
Kleczkowska et al. 2001; Masih et  al. 2008). Direct association of MSH2 and MSH6 with 
replicative DNA polymerases may provide an additional recruitment mechanism. 
In proliferating cells, MMR proteins become increasingly associated with chromatin as S 
phase progresses (Schröering et al. 2007; Mastrocola and Heinen 2010). In this study, this 
was also reflected by the augmented level of MSH proteins in the nucleoprotein fraction of 
HeLa cells in late S phase compared to cells arrested in early S phase (IV; Figure. 5A). The 
analysis of the association of MSH2 with two specific and well-characterised origins of 
replication indicates that MSH2 is recruited to these sites after origin firing. After origin 
firing, ORC2 and MCM3 were released from the origins and from neighbouring regions, 
whereas MSH2 became enriched at these sites. In contrast, the replicative Pols ?, ? and ? 
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became enriched at origin sequences during firing, and rapidly released thereafter, in the 
same way as MCM3 (communicated by H. Pospiech). Although the recruitment of MSH2 
appeared to depend on active DNA replication, MSH2 apparently did not migrate with the 
replication fork. Rather, it was left behind on the replicated chromatin. In summary, results 
presented here, suggest the direct interactions between MSH proteins and replicative DNA 
polymerases described here represent a new, previously unnoticed link between DNA 
replication and mismatch repair. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
Conclusion 1. 
So far, no predisposing MSH3 mutations have been found in Lynch Syndrome patients.  The 
present study shows that in contrast to MutS? (MSH2/MSH6), the MutS? (MSH2/MSH3) 
heterodimer has no role in mononucleotide loop repair but a strong role in dinucleotide loop 
repair, suggesting that MSH3 mutation screening would be important when a tumor shows 
only dinucleotide MSI. Thus, the generally used Bethesda panel including both mono- and 
dinucleotide markers may not be the most suitable to diagnose MSH3 mutation carriers. 
 
Future prospects associated with conclusion 1: 
• To clinically verify the observation by screening MSH3 mutations especially from tumors 
showing instability only in dinucleotide repeats.   
• To study the repair capability of MutS? by using substrates with even longer than 
dinucleotide loops and accordingly its possible association with diseases due to expansion of 
tri- or tetranucleotide repeats.  
 
Conclusion 2. 
Our results show that two inherited MMR gene variations in a cancer patient may have a 
concomitant contribution to MMR deficiency. The role of the frequently reported MMR gene 
VUS MSH2 c.380A>G is especially interesting, since its concomitant defect with another 
variant could finally explain its recurrent occurrence in CRC patients. 
 
Future prospects associated with conclusion 2: 
• Whenever LS is suspected, the all MMR susceptibility genes should be included in mutation 
analyses and the functional significance of all identified VUS should be analyzed. 
• Since epidemiologically it might be of more significance to identify low risk variations with 
high prevalence than high risk rare variations in a population, it could be worth assessing the 
overall significance of MSH2 c.380A>G in CRC risk according to Bayes´ theorem.  
 
Conclusion 3. 
The present functional study shows that Pols ? and ? contribute to but are not essential for 
human MMR, and results suggest that MSH2 and MSH6 physically interact with Pols ? and 
Pol ?, respectively. This is consistent with models where MSH proteins are continuously 
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loaded onto chromatin in a replication-dependent manner, and persist on DNA that has 
already completed replication.  
 
Future prospects associated with conclusion 3: 
• To study the Okazaki fragment formations and the participation of different polymerases 
with the in vitro MMR assay by using different types of substrates. 
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